HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies

This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)

Michael J. Ackerman, MD, PhD,1 Silvia G. Priori, MD, PhD,2 Stephan Willems, MD, PhD,3 Charles Berul, MD, FHRS, CCDS,4 Ramon Brugada, MD, PhD,5 Hugh Calkins, MD, FHR, CCDS,6 A. John Camm, MD, FHR,7 Patrick T. Ellinor, MD, PhD,8 Michael Gollob, MD,9 Robert Hamilton, MD, CCDS,10 Ray E. Hershberger, MD,11 Daniel P. Judge, MD,6,12 Hervê Le Marec, MD,13 William J. McKenna, MD,14 Eric Schulze-Bahr, MD, PhD,15 Chris Semsarian, MBBS, PhD,16 Jeffrey A. Towbin, MD,17 Hugh Watkins, MD, PhD,18 Arthur Wilde, MD, PhD,19 Christian Wolpert, MD,20 Douglas P. Zipes, MD, FHR,21

1From Mayo Clinic, Rochester, Minnesota, 2Fondazione Salvatore Maugeri University of Pavia, Pavia, Italy and New York University, New York, New York, 3University Hospital Hamburg-Eppendorf, Hamburg, Germany, 4Children’s National Medical Center and George Washington School of Medicine, Washington, District of Columbia, 5Girona Institute of Biomedical Research and University of Girona School of Medicine, Girona, Spain, 6Johns Hopkins University, Baltimore, Maryland, 7St. George’s University of London, London, United Kingdom, 8Massachusetts General Hospital, Cardiac Arrhythmia Service, Boston, Massachusetts, 9University of Ottawa Heart Institute, Ottawa, Canada, 10Hospital for Sick Children, Toronto, Canada, 11University of Miami Miller School of Medicine, Miami, Florida, 12Université Paris Descartes, Paris, France, 13Institut du thorax, Nantes Cedex, Nantes, France, 14Institute of Cardiovascular Science, University College London, London, United Kingdom, 15University Hospital Muenster, Muenster, Germany, 16University of Sydney, Sydney, Australia, 17Cincinnati Children’s Hospital, Cincinnati, Ohio, 18University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom, 19University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands, 20Ludwigsburg Clinic, Ludwigsburg, Germany, and 21Kramert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana.

Preamble

This international consensus statement provides the state of genetic testing for the channelopathies and cardiomyopathies. It summarizes the opinion of the international writing group members based on their own experience and on a general review of the literature with respect to the use and role of genetic testing for these potentially heritable cardiac conditions. This document focuses primarily on the state of genetic testing for the 13 distinct entities detailed and the relative diagnostic, prognostic, and therapeutic impact of the genetic test result for each entity. It does not focus on the therapeutic management of the various channelopathies and cardiomyopathies. Treatment/management issues are only discussed for those diseases (i.e., LQTS, HCM, DCM + CCD, RCM) in which the genetic test result could potentially influence treatment considerations.

Writing recommendations for genetic diseases require adaptation of the methodology normally adopted to prepare guidelines for clinical practice. Documents produced by other scientific societies have acknowledged the need to define the criteria used to rank the strength of recommendation for genetic diseases.1

The most obvious difference is that randomized and/or blinded studies do not exist. Instead, most of the available data are derived from registries that have followed patients and recorded outcome information. The authors of this statement have therefore defined specific criteria for Class I, Class IIa or b, and Class III recommendations and have used the conventional language adopted by AHA/ACC/ESC Guidelines to express each class. All recommendations are level of evidence (LOE) C (i.e., based on experts’ opinions).

A Class I recommendation (“is recommended”) was applied for genetic testing in index cases with a sound clinical suspicion for the presence of a channelopathy or a cardiomyopathy when the positive predictive value of a genetic test is high (likelihood of positive result >40% and
signal/noise ratio >10; Table 3), AND/OR when the genetic test result provides either diagnostic or prognostic information, or when the genetic test result influences therapeutic choices according to data in Figure 1 and in Table 3. In all the remaining situations, the authors have used either “can be useful” to articulate either a Class IIa recommendation or “may be considered” to signify a Class IIb recommendation. A Class III (“should not” or “is not recommended”) recommendation was applied in cases in which it was agreed that the genetic test result failed to provide any additional benefit or could be harmful in the diagnostic evaluation of patients with possible inherited heart disease.

Screening of family members for the mutation identified in the proband of the family is recommended as a Class I when genetic testing leads to the adoption of therapy/protective measures/lifestyle adaptations. Conversely, the authors have assigned a Class IIa recommendation when results of genetic testing are not associated with the use of therapeutic or protective measures but the results may be useful for reproductive counseling or instances in which genetic testing is requested by the patient who wants to know his/her mutation status.

When using or considering the guidance from this document, it is important to remember that there are no absolutes governing many clinical situations. The final judgment regarding care of a particular patient must be made by the health care provider and the patient in light of all relevant circumstances. Recommendations are based on consensus of the writing group following the Heart Rhythm Society’s established consensus process. It is recognized that consensus does not mean unanimous agreement among all writing group members. We identified those aspects of genetic testing for which a true consensus could be found. Surveys of the entire writing group were used. The authors received an agreement that was equal to or greater than 84% on all recommendations; most recommendations received agreement of 94% or higher. This statement is directed to all healthcare professionals who are involved with genetic testing for the channelopathies and cardiomyopathies. All members of this document-writing group provided disclosure statements of all relationships that might present real or perceptible conflicts of interest. Disclosures for the members of the task force are published in the Appendix section.

TABLE OF CONTENTS
Introduction and Summary of Expert Consensus Recommendations (see Table 1)

Table 1. Expert Consensus Recommendations

Table 2. Summary of Common Cardiac Channelopathy/Cardiomyopathy-Associated Genes (>5% of Disease)

Table 3. Yield and Signal-to-Noise Associated with Disease-Specific Genetic Testing

I. State of Genetic Testing for Long QT Syndrome (LQTS)
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of LQTS Genetic Testing
      i. Summary of the Common LQTS Genes (see Table 2)
      ii. Index Cases
      iii. Family Screening
   c. Prognostic Implications of LQTS Genetic Testing
   d. Therapeutic Implications of LQTS Genetic Testing

II. State of Genetic Testing for CPVT
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of CPVT Genetic Testing
      i. Summary of the Common CPVT Genes (Table 2)
      ii. Index Cases
      iii. Family Screening
   c. Prognostic and Therapeutic Implications of CPVT Genetic Testing

III. State of Genetic Testing for Brugada Syndrome (BrS)
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of BrS Genetic Testing
      i. Summary of Common BrS Genes (Table 2)
      ii. Index Cases
      iii. Family Screening
   c. Prognostic and Therapeutic Implications of BrS Genetic Testing

IV. State of Genetic Testing for Progressive Cardiac Conduction Disease (CCD)
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of CCD Genetic Testing
      i. Index Cases
      ii. Family Screening
   c. Prognostic and Therapeutic Implications of CCD Genetic Testing

V. State of Genetic Testing for Short QT Syndrome (SQTS)
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of SQTS Genetic Testing
   c. Prognostic and Therapeutic Implications of SQTS Genetic Testing

VI. State of Genetic Testing for Atrial Fibrillation
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of AF Genetic Testing
   c. Prognostic and Therapeutic Implications of AF Genetic Testing

VII. State of Genetic Testing for Hypertrophic Cardiomyopathy (HCM)
   a. Expert Consensus Recommendations
   b. Diagnostic Implications of HCM Genetic Testing
   i. Summary of Common HCM Genes (Table 2)
   ii. Index Cases
   iii. Family Screening
1. Genetic counseling is recommended for all patients and relatives with the familial heart diseases detailed in this document and should include discussion of the risks, benefits, and options available for clinical testing and/or genetic testing.

2. Treatment decisions should not rely solely on his/her genetic test result but should be based on an individual’s comprehensive clinical evaluation.

3. It can be useful for pre-genetic test counseling, genetic testing, and the interpretation of genetic test results to be performed in centers experienced in the genetic evaluation and family-based management of the heritable arrhythmia syndromes and cardiomyopathies described in this document.

See Table 1: Summary of Expert Consensus Recommendations

Since the discovery of the first cardiomyopathy-causative gene in 1990 and the sentinel channelopathy-causative genes in 1995, genetic testing for potentially heritable channelopathies and cardiomyopathies has advanced from basic scientific discovery to clinical application. Today, the majority of channelopathy/cardiomyopathy genetic tests are clinically available diagnostic tests. This maturation requires cardiologists and heart rhythm specialists to acquire a new vocabulary, the language of genomic medicine.

There is a substantial knowledge gradient among cardiologists regarding heritable channelopathies and cardiomyopathies. Among heart rhythm specialists, it is estimated that less than 20% of a pediatric electrophysiologist’s training and less than 10% of an adult electrophysiologist’s training pertains to the heritable channelopathies such as long QT syndrome. With the complexities of genetic testing, it will be essential for training programs to address and bridge these knowledge gaps.

Genetic counseling is recommended for all patients and relatives with the familial heart diseases detailed in this statement. Counseling should include a thorough discussion of the risks, benefits, and options available for clinical genetic testing.

The broader ethical, legal, and societal implications (ELSI) of genetic testing are beyond the scope of this document and a variety of national regulations and specifications exist. Questions regarding the possibility of and role for pre-implantation genetic testing of embryos generated with assisted reproductive technologies are emerging. If the electrophysiologist or cardiologist is not equipped to discuss these issues, genetic counseling should be done in partnership with genetic counselors, nurse–geneticists, and/or geneticists. Such a multidisciplinary approach may help serve the needs of the index
### Table 1  Summary of Expert Consensus Recommendations

<table>
<thead>
<tr>
<th>Condition</th>
<th>Class I (is recommended)</th>
<th>Class IIa (can be useful)</th>
<th>Class IIb (may be considered)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR LONG QT SYNDROME (LQTS)</strong></td>
<td>Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing is recommended for any patient in whom a cardiologist has established a clinical index of suspicion for LQTS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative stress testing with exercise or catecholamine infusion) phenotype.</td>
<td>Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the LQTS-causative mutation in an index case.</td>
<td>Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing may be considered for any asymptomatic patient with otherwise idiopathic QTc values &gt;460 ms (prepuberty) or &gt;480 ms (adults) on serial 12-lead ECGs.</td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR BRUGADA SYNDROME (BrS)</strong></td>
<td>Mutation-specific genetic testing is recommended for any patient in whom a cardiologist has established a clinical index of suspicion for BrS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic phenotype during provocative stress testing with cycle, treadmill, or catecholamine infusion.</td>
<td>Genetic testing may be considered as part of the diagnostic evaluation for patients with either isolated BrS or BrS with concomitant congenital heart disease, especially when there is documentation of a positive family history of BrS.</td>
<td>Comprehensive or BrS1 (SCN5A) targeted BrS genetic testing can be useful for any patient in whom a cardiologist has established a clinical index of suspicion for BrS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic phenotype during provocative stress testing with cycle, treadmill, or catecholamine infusion.</td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)</strong></td>
<td>Mutation-specific genetic testing is recommended for any asymptomatic patient with otherwise idiopathic CPVT phenotype.</td>
<td>Genetic testing is not indicated/recommended in the setting of an isolated type 2 or type 3 Brugada ECG pattern.</td>
<td></td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR SHORT QT SYNDROME (SQTS)</strong></td>
<td>Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case.</td>
<td></td>
<td>Comprehensive or SQT1-3 (KCNH2, KCNQ1, and KCN2) targeted SQTS genetic testing may be considered for any patient in whom a cardiologist has established a strong clinical index of suspicion for SQTS based on examination of the patient’s clinical history, family history, and electrocardiographic phenotype.</td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR PROGRESSIVE CARDIAC CONDUCTION DISEASE (CCD)</strong></td>
<td></td>
<td></td>
<td>Comprehensive or targeted (MYBPC3, MYH7, TNNI3, TNNT2, TPM1) CCD genetic testing is recommended for any patient in whom a cardiologist has established a clinical diagnosis of CCD based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR ATRIAL FIBRILLATION</strong></td>
<td>Genetic testing is not indicated for atrial fibrillation at this time. SNP genotyping in general and SNP rs2200733 genotyping at the 4q25 locus in particular for AF is not indicated at this time based on the limited outcome data currently available.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR HYPERTROPHIC CARDIOMYOPATHY (HCM)</strong></td>
<td>Comprehensive or targeted (MYBPC3, MYH7, TNNI3, TNNT2, TPM1) HCM genetic testing is recommended for any patient in whom a cardiologist has established a clinical diagnosis of HCM based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STATE OF GENETIC TESTING FOR ARRHYTHMOGENIC CARDIOMYOPATHY (ACM)/ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC)</strong></td>
<td>Mutation-specific genetic testing is recommended for any patient in whom a cardiologist has established a clinical diagnosis of ACM/ARVC based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td>
<td>Comprehensive or targeted (DSG2, DSP, JUP, PKP2, and TMEM43) ACM/ARVC genetic testing can be useful for patients satisfying task force diagnostic criteria for ACM/ARVC.</td>
<td>Genetic testing may be considered for patients with possible ACM/ARVC (1 major or 2 minor criteria) according to the 2010 task force criteria (European Heart Journal).</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Genetic testing is not recommended for patients with only a single minor criterion according to the 2010 task force criteria.</td>
<td></td>
</tr>
</tbody>
</table>
cases and their families more fully. In addition, it can be helpful for pre-genetic test counseling, genetic testing, and the interpretation of genetic test results to be performed in centers experienced in the genetic evaluation and family-based management of the heritable arrhythmia syndromes and cardiomyopathies described in this statement.

Genetic testing must not be viewed as a one-size-fits-all solution. There are more than 50 distinct channelopathy/cardiovascularopathy-associated genes with hundreds of discrete missense, nonsense, insertion/deletion, frameshift, and splice site mutations. Table 2 summarizes only the common disease-associated genes responsible for ≳5% of a given disease that is detailed in this consensus statement. In addition, the yield of genetic testing is disease dependent ranging among the channelopathies from <20% for short QT syndrome to 75% for the current generation long QT syndrome genetic test. Among the cardiomyopathies, the yields range from <20% for restrictive cardiomyopathy to 60% for familial hypertrophic cardiomyopathy (Table 3). Consequently, a negative genetic test can never, by itself, rule out the presence of any of the diseases under consideration for the index case. When caring for a patient with an unequivocal disease phenotype but a negative genetic test, non-genetic cardiologists from this writing group without a direct or potential conflict of interest (Drs. A.J. Camm and D. Zipes) encourage physicians to seek out research laboratories that look for novel disease-causing genes for the patient’s particular disease.

In addition, the diagnostic, prognostic, and therapeutic contribution of a genetic test result also is disease dependent for the index case (Figure 1). The impact of each disease-specific genetic test in each of these three areas is detailed in each section of this document. This triad is satisfied most fully for long QT syndrome. Regardless of the disease in question or the specific genetic test pursued, treatment decisions should not rely solely on the patient’s genetic test result but should be based on results from his/her comprehensive clinical evaluation.

The correct identification of the definitive disease-causing mutation in an index case potentially affords a gold standard diagnostic marker for the presence or absence of the patho-

Table 1  Continued

<table>
<thead>
<tr>
<th>STATE OF GENETIC TESTING FOR DILATED CARDIOMYOPATHY (DCM)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I (is recommended)</td>
<td>Comprehensive or targeted (LMNA and SCN5A) DCM genetic testing <strong>is recommended</strong> for patients with DCM and significant cardiac conduction disease (i.e., first-, second-, or third-degree heart block) and/or a family history of premature unexpected sudden death. Mutation-specific genetic testing <strong>is recommended</strong> for family members and appropriate relatives following the identification of a DCM-causative mutation in the index case.</td>
</tr>
<tr>
<td>Class IIa (can be useful)</td>
<td>Genetic testing <strong>can be useful</strong> for patients with familial DCM to confirm the diagnosis, to recognize those who are at highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family, and to help with family planning.</td>
</tr>
</tbody>
</table>

STATE OF GENETIC TESTING FOR LEFT VENTRICULAR NONCOMPACTION (LVNC) |  |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I (is recommended)</td>
<td>Mutation-specific genetic testing <strong>is recommended</strong> for family members and appropriate relatives following the identification of a LVNC-causative mutation in the index case.</td>
</tr>
<tr>
<td>Class IIa (can be useful)</td>
<td>LVNC genetic testing <strong>can be useful</strong> for patients in whom a cardiologist has established a clinical diagnosis of LVNC based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td>
</tr>
</tbody>
</table>

STATE OF GENETIC TESTING FOR RESTRICTIVE CARDIOMYOPATHY (RCM) |  |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I (is recommended)</td>
<td>Mutation-specific genetic testing <strong>is recommended</strong> for family members and appropriate relatives following the identification of a RCM-causative mutation in the index case.</td>
</tr>
<tr>
<td>Class IIb (may be considered)</td>
<td>RCM genetic testing <strong>may be considered</strong> for patients in whom a cardiologist has established a clinical index of suspicion for RCM based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.</td>
</tr>
</tbody>
</table>

STATE OF GENETIC TESTING FOR OUT-OF-HOSPITAL CARDIAC ARREST SURVIVORS |  |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I (is recommended)</td>
<td>In the survivor of an Unexplained Out-of-Hospital Cardiac Arrest, genetic testing <strong>should be</strong> guided by the results of medical evaluation and is used for the primary purpose of screening at-risk family members for subclinical disease.</td>
</tr>
<tr>
<td>Class III (is not indicated/recommended)</td>
<td>Routine genetic testing, in the absence of a clinical index of suspicion for a specific cardiomyopathy or channelopathy, <strong>is not indicated</strong> for the survivor of an Unexplained Out-of-Hospital Cardiac Arrest.</td>
</tr>
</tbody>
</table>

STATE OF POST-MORTEM GENETIC TESTING IN SUDDEN UNEXPECTED DEATH CASES (SUD/SIDS) |  |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I (is recommended)</td>
<td>For all SUDs and SIDS cases, collection of a tissue sample <strong>is recommended</strong> (5–10 mL whole blood in EDTA tube, blood spot card, or a frozen sample of heart, liver, or spleen) for subsequent DNA analysis/genetic testing. Mutation-specific genetic testing <strong>is recommended</strong> for family members and other appropriate relatives following the identification of a SUDS-causative mutation in the decedent.</td>
</tr>
<tr>
<td>Class IIb (may be considered)</td>
<td>In the setting of autopsy negative SUDS, comprehensive or targeted (RYR2, KCNQ1, KCNH2, and SCN5A) ion channel genetic testing <strong>may be considered</strong> in an attempt to establish probable cause and manner of death and to facilitate the identification of potentially at-risk relatives and is recommended if circumstantial evidence points toward a clinical diagnosis of LQTS or CPVT specifically (such as emotional stress, acoustic trigger, drowning as the trigger of death).</td>
</tr>
</tbody>
</table>
genic substrate among relatives. Accordingly, genetic testing in individuals with the familial diseases outlined in this document may be useful to identify at-risk family members, to identify the cause of their condition, to determine their likelihood of syndromic disease manifestations, and to assist with family planning. Consequently, mutation-specific genetic testing among the family members has diagnostic, prognostic, and therapeutic implications ranging from a negative genetic test and potential dismissal from cardiology to a positive genetic test in a relative without clinical evidence for the disease in question that results in prophylactic treatment. However, the age at genetic testing and use of genetic testing for asymptomatic family members and other relatives without a manifest diagnosis are disease dependent. For diseases such as long QT syndrome and catecholaminergic polymorphic ventricular tachycardia, in which preventive measures or prophylactic

<table>
<thead>
<tr>
<th>Section I – Long QT Syndrome (LQTS)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>KCNQ1 (LQT1)</td>
<td>11p15.5</td>
<td>I_K, potassium channel alpha subunit (Kv7.1)</td>
<td>30%–35%</td>
<td></td>
</tr>
<tr>
<td>KCNH2 (LQT2)</td>
<td>7q35-q36</td>
<td>I_K, potassium channel alpha subunit (Kv11.1 or hERG)</td>
<td>25%–40%</td>
<td></td>
</tr>
<tr>
<td>SCN5A (LQT3)</td>
<td>3p21</td>
<td>Cardiac sodium channel alpha subunit (NaV1.5)</td>
<td>5%–10%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section II – Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>RYR2 (CPVT1)</td>
<td>1q42.1-q43</td>
<td>Ryanodine receptor 2</td>
<td>60%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section III – Brugada Syndrome (BrS)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCN5A</td>
<td>3p21</td>
<td>Cardiac sodium channel alpha subunit (NaV1.5)</td>
<td>20%–30%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section IV – Cardiac Conduction Disease (CCD)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCN5A</td>
<td>3p21</td>
<td>Cardiac sodium channel alpha subunit (NaV1.5)</td>
<td>5%</td>
<td></td>
</tr>
</tbody>
</table>

| Section V – Short QT Syndrome (SQTS) | None of the known disease-associated genes has been shown to account for ≥5% of this disease |

| Section VI – Atrial Fibrillation (AF) | None of the known disease-associated genes has been shown to account for ≥5% of this disease |

<table>
<thead>
<tr>
<th>Section VII – Hypertrophic Cardiomyopathy (HCM)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYBPC3</td>
<td>11p11.2</td>
<td>Cardiac myosin-binding protein C</td>
<td>20%–45%</td>
<td></td>
</tr>
<tr>
<td>MYH7</td>
<td>14q11.2-q12</td>
<td>β-Myosin heavy chain</td>
<td>15%–20%</td>
<td></td>
</tr>
<tr>
<td>TNNT2</td>
<td>1q32</td>
<td>Cardiac troponin T type 2</td>
<td>1%–7%</td>
<td></td>
</tr>
<tr>
<td>TNNI3</td>
<td>19q13.4</td>
<td>Cardiac troponin I type 3</td>
<td>1%–7%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section VIII – Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKP2</td>
<td>12p11</td>
<td>Plakophilin 2</td>
<td>25%–40%</td>
<td></td>
</tr>
<tr>
<td>DSG2</td>
<td>18q12.1</td>
<td>Desmoglein 2</td>
<td>5%–10%</td>
<td></td>
</tr>
<tr>
<td>DSP</td>
<td>6p24</td>
<td>Desmoplakin</td>
<td>2%–12%</td>
<td></td>
</tr>
<tr>
<td>DSC2</td>
<td>18q12.1</td>
<td>Desmocollin 2</td>
<td>2%–7%</td>
<td></td>
</tr>
</tbody>
</table>

| Section IX – Dilated Cardiomyopathy (DCM) | None of the >25 known disease-associated genes has been shown to account for ≥5% of this disease |

<table>
<thead>
<tr>
<th>Section IX – Dilated Cardiomyopathy with Cardiac Conduction Defect (DCM + CCD)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCN5A</td>
<td>3p21</td>
<td>Cardiac sodium channel alpha subunit (NaV1.5)</td>
<td>5%–10%</td>
<td></td>
</tr>
<tr>
<td>LMNA</td>
<td>1q22</td>
<td>Lamin A/C</td>
<td>5%–10%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section X – Left Ventricular Non-Compaction (LVNC)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>LBD3</td>
<td>10q22.2-q23.3</td>
<td>LIM binding domain 3</td>
<td>~5%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section XI – Restrictive Cardiomyopathy (RCM)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYH7</td>
<td>14q11.2-q12</td>
<td>β-Myosin heavy chain</td>
<td>~5%</td>
<td></td>
</tr>
<tr>
<td>TNNI3</td>
<td>19q13.4</td>
<td>Cardiac troponin I type 3</td>
<td>~5%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section XIII – Sudden Unexplained Death Syndrome (SUDS)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>RYR2</td>
<td>1q42.1-q43</td>
<td>Ryanodine Receptor 2</td>
<td>10%–15%</td>
<td></td>
</tr>
<tr>
<td>KCNQ1</td>
<td>11p15.5</td>
<td>I_K, potassium channel alpha subunit (Kv7.1)</td>
<td>5%–10%</td>
<td></td>
</tr>
<tr>
<td>KCNH2</td>
<td>7q35-q36</td>
<td>I_K, potassium channel alpha subunit (Kv11.1 or hERG)</td>
<td>~5%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Section XIII – Sudden Infant Death Syndrome (SIDS)</th>
<th>Gene</th>
<th>Locus</th>
<th>Protein</th>
<th>% of Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCN5A</td>
<td>3p21</td>
<td>Cardiac sodium channel alpha subunit (NaV1.5)</td>
<td>3%–5%</td>
<td></td>
</tr>
</tbody>
</table>
Many positive test results contain the index case’s and his/her family’s definitive disease-causing mutation, the proverbial pathogenic “smoking gun.” However, many so-called “positive” test results are represented by less informative DNA variants currently annotated with the expression “Variants of Uncertain Significance” (VUS). Only recently is the frequency of rare VUS among otherwise healthy volunteers across the exomes of various disease-causing genes being identified.9–12

Table 3 summarizes the known background frequency of rare VUS for the common disease-associated genes, which enables an initial estimate of the “signal-to-noise” ratio for the various genetic tests. As commercialized disease-specific gene panels increase to include the minor disease-associated genes in which each gene is responsible for <1% of the disease in question, this “signal-to-noise” ratio potentially declines because many of these minor genes are often paradoxically accompanied with a measurable frequency of VUS.

This VUS issue and its associated possibility of a false positive genetic test results are also disease dependent, ranging from a relatively low rate of false positives for CPVT testing to an alarmingly high rate of possible false positives associated with the ACM/ARVC test. A false positive involves the identification of a rare but otherwise non-pathogenic mutation. For many disease-specific genetic tests, the false positive rate is unknown. The potential for false positive genetic test results rises significantly when genetic testing is pursued in settings in which the phenotype is ambiguous or absent, such as in screening. Consequently, there is no role for universal genetic testing for any of the diseases detailed in this statement. Instead,
genetic testing must be phenotype directed. If the clinical diagnosis is in question, it may be prudent first to refer the patient to a center specializing in that particular disease rather than proceeding directly with genetic testing.

Genetic testing must not be viewed as a simple blood test. Genetic testing for the diseases outlined in this document need to be approached as one component of a comprehensive cardio-genetic evaluation in which all the aforementioned issues, including (a) the certainty and expertise of proband diagnosis, (b) the probabilistic nature of genetic testing and the need for pre-test counseling to inform the patient of the intrinsic uncertainties of genetic testing, and (c) the need to obtain a family history to get a sense of disease penetrance and expressivity, are addressed with care.

I. STATE OF GENETIC TESTING FOR LONG QT SYNDROME (LQTS)

Expert Consensus Recommendations

1. Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing is recommended for any patient in whom a cardiologist has established a strong clinical index of suspicion for LQTS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative stress testing with exercise or catecholamine infusion) phenotype.

2. Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing is recommended for any asymptomatic patient with QT prolongation in the absence of other clinical conditions that might prolong the QT interval (such as electrolyte abnormalities, hypertrophy, bundle branch block, etc., i.e., otherwise idiopathic) on serial 12-lead ECGs defined as QTC >480 ms (prepuberty) or >500 ms (adults).

3. Comprehensive or LQT1-3 (KCNQ1, KCNH2, and SCN5A) targeted LQTS genetic testing may be considered for any asymptomatic patient with otherwise idiopathic QTc values >460 ms (prepuberty) or >480 ms (adults) on serial 12-lead ECGs.

4. Mutation-specific genetic testing is recommended for family members and other appropriate relatives subsequently following the identification of the LQTS-causative mutation in an index case.

Congenital long QT syndrome (LQTS) is a genetic disease characterized by its hallmark electrocardiographic feature of QT prolongation and T wave abnormalities, its trademark arrhythmia of torsades de pointes (TdP), and its predisposition for syncope, “seizures,” and sudden cardiac death (SCD) in young individuals with structurally normal hearts.13 The majority of LQTS index cases manifest diagnostic QT prolongation on their resting 12-lead ECG, while approximately 10 to 40% of LQTS patients (index cases and relatives) have non-diagnostic QT intervals at rest and are referred to as “normal QT interval” or “concealed” LQTS.14–17 Besides needing to verify the computer derived QTc value manually, careful inspection of T wave and U wave morphology is necessary to detect subtle clues regarding the possible presence of LQTS. Exercise testing, catecholamine stress testing, and Holter monitoring may increase diagnostic sensitivity in some patients.18–22 A clinical diagnostic score, developed before genetics entered the field of LQTS, still is used in clinics to help in establishing the diagnosis.23 Secondary causes have to be excluded as the cause for repolarization changes.

With an estimated incidence of at least 1 in 2,500 people,24 LQTS is underscored by marked clinical heterogeneity ranging from a lifelong asymptomatic state to sudden death during infancy. LQTS is more likely to express itself before puberty in males and after puberty in females.17,25,26 Besides age and sex, the degree of QTc prolongation is associated with likelihood of a first LQT-triggered cardiac event (syncope or aborted cardiac arrest) while occurrence of such cardiac events, particularly while on therapy, is a strong predictor of recurrences.27–29 Among symptomatic index cases, the untreated 10-year mortality is approximately 50%.28–31

Diagnostic Implications of LQTS Genetic Testing

Summary of the Common LQTS Genes (see Table 2)

Since the sentinel discovery of the primary LQTS-causative genes in 199530,32 and 1996,33 at least 13 LQTS genes have been reported.34–40 Comprehensive open reading frame analysis of the three canonical LQTS-causative genes—KCNQ1-encoded Kv7.1 channel subunit (LQT1), KCNH2-encoded Kv11.1 (LQT2), and SCN5A-encoded Nav1.5 (LQT3)—yields putative LQTS-associated mutations in 75% of clinically definite LQTS (Table 2).15,41 This yield may increase to 80% with inclusion of copy number variant (CNV)/genomic rearrangement testing of KCNQ1 and KCNH2.42,43 Thus, nearly 70% of all LQTS stems from loss-of-function mutations involving either the Kv7.1 (IKs) potassium channel (LQT1) or the Kv11.1 (IKr) potassium channel (LQT2) while approximately 5%–10% is secondary to “gain-of-function” mutations in the Nav1.5 (INa) sodium channel (LQT3). The 10 additional minor LQTS genes comprise <5% of LQTS cases.

As such, approximately 15% to 20% of LQTS remains genetically elusive following comprehensive genetic testing of the currently known genes. The majority of LQTS is inherited as an autosomal dominant trait, the Romano-Ward syndrome. Sporadic (or de novo) alterations occur <5%–10% of the time. Extrapolating from the established prevalence of LQTS in general, the autosomal recessive form of LQTS, also known as Jervell and Lange-Nielsen syndrome, probably affects less than 1 in a million people and results from complete loss of Kv7.1 channel function, which precipitates sensorineural deafness in addition to LQT1 or LQT3 substrates associated with increased cardiac risk.44,45

In addition to autosomal dominant and autosomal recessive LQTS, Andersen-Tawil syndrome (ATS) and Timothy syndrome (TS) have been classified in the past as LQT7 and LQT8, respectively. The cardiac phenotype of ATS includes...
abnormal TU waves and QTU prolongation. ATS1 (LQT7) stems from mutations in the KCNJ2-encoded Kir2.1 potassium channel and accounts for approximately 50% to 60% of ATS. TS involves marked QT prolongation and synce- tyly. TS1 (LQT8) is the result of gain-of-function mutations in the CACNA1C-encoded L-type calcium channel subunit.

**Index Cases**

Following the era of research-based genetic testing, LQTS genetic testing has been a clinically available, fee-for-service diagnostic test for the past 5–10 years. Genetic analysis of KCNQ1, KCNH2, and SCN5A including CNV testing for KCNQ1 and KCNH2 genomic rearrangements will yield possible LQT1-, LQT2-, and LQT3-causative mutation(s) for 75% to 80% of patients with a robust LQTS phenotype. While addition of the 10 minor LQTS genes increases the yield by <5%, it significantly increases the chances of a false positive. Accordingly, either comprehensive genetic testing of all known LQTS genes or targeting the three major LQTS genotypes are acceptable strategies. As with every condition in this statement, a negative genetic test cannot exclude unequivocally the diagnosis of LQTS by itself.

Clinical LQTS genetic testing is recommended for any index case in which LQTS is suspected by a cardiologist based on the patient’s clinical history, family history, QT interval duration, inspection of T-wave morphology, and/or response to either cycle/treadmill or catecholamine stress testing. If that patient was tested previously in a research laboratory, testing should be repeated with an LQTS genetic test. The sensitivity of current clinical LQTS genetic tests is superior to the research-based genetic tests that were available in the 1990s and early 2000s. If a patient has exercise-triggered cardiac events, a mildly prolonged or normal resting QTc (usually <460 ms) and exercise-induced multif orm PVCs, the diagnosis of catecholaminergic polymorphic ventricular tachycardia (CPVT) or Andersen-Tawil syndrome (ATS1/LQT7) in combination with other clinical signs also should be considered (see Section II on CPVT).50,51

LQTS genetic testing should not be performed solely in response to a past history of fainting without cardiology consultation. It must not be performed as part of pre-sports participation or as a universal screening protocol. The significant rate of rare variants of uncertain significance (i.e., non-synonymous genetic variation: 4% in whites and 6% to 8% in non-whites) in the LQT1–3 genes complicates correct mutation assignment and mandates that LQTS genetic testing be sought based on clinical suspicion rather than ordered indiscriminately. In some countries, there are strict legal restrictions against performing genetic testing in the absence of evidence/suspected disease or of a proven gene mutation in a close family relative.

Even in the absence of symptoms, LQTS genetic testing is recommended for patients with unequivocal and otherwise idiopathic, serial QT prolongation (QTc ≥480 ms in prepubertal children and ≥500 ms in adults). Otherwise idiopathic implies that the QT prolongation cannot be attributed to disease states/conditions (e.g., electrolyte abnormal-}

**Prognostic Implications of LQTS Genetic Testing**

Numerous genotype-phenotype relationships in LQTS have been discovered in the past 15 years, including genotype-
suggestive ECG patterns, genotype-suggestive arrhythmogenic triggers, genotype-based natural histories, and genotype-specific responses to pharmacotherapy. The majority of these relationships pertain to the major LQTS genotypes: LQT1, LQT2, and LQT3. The genetic test result has joined traditional risk factors (i.e., gender, age at onset, QTc at rest, syncope) as independent prognostic risk factors. Compared with the more common potassium channel loss-of-function subtypes (LQT1 and LQT2), patients with LQT3 appear to have the highest mortality per event. In addition, within each of the two major LQTS genotypes (LQT1 and LQT2), the mutation’s location within the protein and its functional sequelae have been proposed as independent risk factors with hazards ratios similar to the QTc >500 ms risk factor. Besides an observed risk stratifying class effect based on mutation type, mutation location, and mutation’s impact on cellular function, mutation-specific risk stratification has emerged for a few discrete LQTS-causative mutations (e.g., A341V-KCNQ1, E1784K-SCN5A).

Therapeutic Implications of LQTS Genetic Testing

Beta blocker pharmacotherapy is the primary treatment for the management of most patients with LQTS. Among the three most common genotypes, beta blockers are extremely protective in LQT1 patients and moderately protective in LQT2. In contrast, targeting of the pathologic, LQT3-associated late sodium current with propranolol (as the preferred beta blocker) and the possible addition of mexiletine, flecainide, or ranolazine represents the preferred pharmacotherapeutic option for LQT3. Although genotype and mutation data must be incorporated with all of other non-genetic risk factors in assessing the patient’s risk and personalizing the patient’s treatment plan, no treatment decision should be influenced solely by either the genotype (LQT1-3) or the specific LQTS-causative mutation that was identified. In particular, a decision to implant an ICD prophylactically in an asymptomatic LQT3 host must include risk factors besides LQT3 genotype status.

II. STATE OF GENETIC TESTING FOR CPVT

Expert Consensus Recommendations

1. Comprehensive or CPVT1 and CVPT2 (RYR2 and CASQ2) targeted CPVT genetic testing is recommended for any patient in whom a cardiologist has established a clinical index of suspicion for CPVT based on examination of the patient’s clinical history, family history, and expressed electrocardiographic phenotype during provocative stress testing with cycle, treadmill, or catecholamine infusion.

2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the CPVT-causative mutation in an index case.

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a genetic disease characterized by adrenergically mediated ventricular arrhythmias causing syncope, cardiac arrest, and sudden cardiac death (SCD) in young individuals with structurally normal hearts. Symptoms typically occur with exertion or emotional stress. CPVT patients manifest with a normal resting ECG but exercise stress testing can elicit the typical bi-directional or polymorphic ventricular tachycardia. However, exercise-induced, single premature ventricular contractions (PVCs) or PVCs in bigeminy may be the only expression of the CPVT substrate. Ventricular fibrillation occurring during stress or emotion is the first manifestation of the disease in a minority of individuals. Holter monitoring may be useful in some patients to document catecholamine-related arrhythmias.

Supraventricular arrhythmias, ranging from isolated premature atrial contractions to runs of supraventricular tachycardia and bursts of atrial fibrillation, also are common in CPVT, stereotypically elicited by exercise or emotions. The concomitant presence of supraventricular arrhythmias also has been seen in LQTS, BrS, and HCM.

The mean age of onset of symptoms is 8 years old, but the first syncopal event may not occur until adulthood in some instances. Approximately 30% of affected individuals have symptoms before age 10 and nearly 60% of patients have at least one syncopal episode before age 40.

Diagnostic Implications of CPVT Genetic Testing

Summary of the Common CPVT Genes (Table 2)

Two CPVT genetic variants have been identified: an autosomal dominant form, due to mutations in the gene encoding for the cardiac ryanodine receptor (RYR2), and a less common autosomal recessive form, resulting from mutations in the gene for cardiac calsequestrin (CASQ2).

Index Cases

Approximately 65% of CPVT index cases have a RYR2 mutation while the prevalence of CASQ2 mutations is low, estimated at approximately 3% to 5%. Genetic screening allows the identification of mutations in up to 65% of patients with a clinical diagnosis. More than 100 RYR2 mutations have been reported as causative for the dominant form of CPVT (CPVT1). They tend to affect specific clusters/regions of the protein, primarily the FKBP12.6 binding domain, codons 2200–2500, and the transmembrane segments and C-terminus, starting from codon 3700. Therefore, because of the very large size of the RYR2 gene, some laboratories only provide screening of selected exons encompassing these critical regions. Tiered screening has been proposed with subsequent screens encompassing the majority of RYR2. Given the evidence that mutations outside the “clusters” have been identified, a CPVT genetic test that targets only a specific set of RYR2’s 105 translated exons may be suboptimal.

CASQ2 maps on chromosome 1p13.3-p11 and is the gene that causes the autosomal recessive form of CPVT (CPVT2). CASQ2 is rare; as a consequence, only 12 CPVT-associated mutations and three non-synonymous polymorphisms (cSNP) have been shown to affect this gene (www.fsm.it/cardmoc).
Because it is unclear whether CASQ2 mutations may also cause autosomal dominant transmission of the phenotype and cases of double heterozygosity in non-consanguineous families have been reported,81 it is rational to screen CASQ2 in sporadic RYR2-negative index cases.

Sudden cardiac arrest can be the first clinical presentation in up to 30% of cases.76 Therefore, RYR2 mutations may be considered in first-degree relatives, even with a negative family history.82 Genetic testing is recommended in such instances. The yield of genetic testing in CPVT is the highest (65%) and most cost-effective among patients with typical bi-directional VT while for patients with non-typical clinical presentation (adrenergically induced syncpe or IVF) the yield is much lower (<15%).79 Of note, instances of SIDS have been associated with mutations in RYR2,82 but it is still unclear whether systematic RYR2 screening is indicated and cost-effective for this population.

More recently, it has been proposed that mutations in other genes may cause an arrhythmogenic disorder that resembles the classic description of CPVT (phenocopies): KCN2-encoding the Kir2.1 potassium channel that conducts I_{K1} and ANKB encoding for ankyrin B, a cytoskeletal protein.83,84 There is no definitive indication for a systematic screening of these genes in CPVT patients. However, if the primary RYR2 genetic test is negative, careful consideration for a CPVT phenocopy should be given. If there is an abundance of ectopy present on 24-hour ambulatory monitoring, and prominent U wave, consider KCN2 testing.

Family Screening

When a likely pathogenetic mutation is identified in clinically affected index cases, screening of all first-degree relatives is indicated. In addition, both first- and second-degree relatives should undergo clinical and genetic evaluation, including exercise stress testing when possible. Genetic testing for RyR2 and CASQ2 mutations should also be considered in first-degree relatives, even with a negative clinical phenotype.

Prognostic and Therapeutic Implications of CPVT Genetic Testing

There is no straightforward genotype-based risk stratification in CPVT. There also is no differential treatment approach presently for a CPVT1-positive index case compared to the CPVT index case with a negative genetic test. However, because CPVT may cause sudden death as first manifestation, genetic testing has relevance for clinical management and therapeutic decisions involving family members. Early CPVT genetic evaluation is important for all family members of CPVT index cases, facilitating pre-symptomatic diagnosis, appropriate counseling, and initiation of prophylactic beta blocker therapy. Considering the early age of manifestation of CPVT and its association with SIDS, it is reasonable that in families with a known CPVT-associated mutation, confirmatory genetic testing should be performed at birth to allow prompt initiation of beta blocker therapy in mutation-positive subjects.

III. STATE OF GENETIC TESTING FOR BRUGADA SYNDROME (BrS)

Expert Consensus Recommendations

1. Comprehensive or BrS1 (SCN5A) targeted BrS genetic testing can be useful for any patient in whom a cardiologist has established a clinical index of suspicion for BrS based on examination of the patient’s clinical history, family history, and expressed electrocardiographic (resting 12-lead ECGs and/or provocative drug challenge testing) phenotype.
2. Genetic testing is not indicated in the setting of an isolated type 2 or type 3 Brugada ECG pattern.
3. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the BrS-causative mutation in an index case.

Brugada syndrome (BrS) is characterized by right precordial ST elevation, frequently associated with conduction delays at different cardiac levels, potentially lethal arrhythmias, and a positive family history for sudden premature death.85,86 BrS typically expresses in males in their third to fourth decade of life and is responsible for a significant subset of sudden death in young individuals. The prevalence of the disease manifesting with clinical symptoms is estimated to be 1 in 5,000 to 10,000 in Western countries and may be more prevalent in South Asia. On the other side, the prevalence of clinically silent type 1 Brugada ECG pattern is likely much higher.87 Phenotypic expression of BrS is rare in children.

Risk stratification is based on clinical parameters, particularly symptoms. Previous cardiac arrest and syncope put affected individuals at risk for recurrent (lethal) events.86,88 The role of other parameters, including the outcome of invasive electrophysiological studies, is disputed.86–92 Treatment of high-risk patients consists of ICD implantation. Some researchers advocate a role for quinidine, particularly for low- to intermediate-risk patients.93

Diagnostic Implications of BrS Genetic Testing

Summary of Common BrS Genes (Table 2)

At least eight genes may be causally involved. SCN5A, the gene encoding the cardiac sodium channel, accounts for the vast majority (>75%) of BrS genotype positive cases (Table 2). However, the yield of SCN5A genetic testing for robust clinical cases of BrS is approximately 25%.94 Thus, the majority (>65%) of BrS cases remain genetically elusive.

Index Cases

The diagnosis of BrS is a clinical diagnosis and requires the signature type 1 Brugada ECG pattern in combination with one or more clinical variables such as unexplained syncope and family history of premature unexplained sudden death.86 Genetic testing is not involved in the diagnosis, but the identification of a causative mutation may help confirm
a clinically uncertain diagnosis. The involvement of loss-of-function sodium channel mutations, the predominant genetic cause of BrS, may be recognized by more or less discrete conduction disorders at different levels of the heart. Involvement of the calcium channel genes in patients with Brugada syndrome seems to be associated with relatively short QT intervals.

**Family Screening**

Genetic testing in families with an underlying causal gene defect may play a decisive role in who should take precautions in appropriate conditions (see below) and who should be followed.

**Prognostic and Therapeutic Implications of BrS Genetic Testing**

Data coupling genetic status to prognosis are scarce. Different outcomes as a function of the underlying gene defect have not been reported, and in a meta-analysis there seems to be no difference whether SCN5A is involved (BrS1). However, in a subset analysis of patients with SCN5A-mediated BrS (i.e., BrS1), there may be a slightly better prognosis in cases of a SCN5A missense mutation compared with those leading to a truncated protein. The latter also associates with more conduction delay (at different levels in the heart) than the former.

As there is no prognostic value of a genetic diagnosis, the presence of a BrS-associated mutation does not impact the treatment of an index case with BrS. However, asymptomatic SCN5A mutation-positive subjects also are advised to avoid or prevent fever and, if body temperature rises, to use antipyretic treatment liberally. Drugs that decrease sodium channel availability/functionality should be avoided by patients with BrS regardless of symptom status or electrocardiographic manifestation. Both precautions are probably relevant for all patients with clinically diagnosed BrS independent of their genetic status.

**IV. STATE OF GENETIC TESTING FOR PROGRESSIVE CARDIAC CONDUCTION DISEASE (CCD)**

**Expert Consensus Recommendations**

1. Genetic testing may be considered as part of the diagnostic evaluation for patients with either isolated CCD or CCD with concomitant congenital heart disease, especially when there is documentation of a positive family history of CCD.

2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the CCD-causative mutation in an index case.

This section pertains to familial forms of conduction disease, not to (common) non-familial forms secondary to structural heart disease. Cardiac conduction disorders (CCDs) typically are characterized by a delay in electrical impulse conduction at the atrial, nodal, and ventricular levels. In the surface ECG, CCDs can be seen by a prolonged P-wave duration, PQ interval and QRS widening with axis deviation. Often, not all ECG changes initially are present and progressively develop an age-dependent penetrance.

In isolated forms of CCD, there are no extracardiac manifestations. The heart is structurally normal. ECG signs may include atrial inexcitability (atrial standstill), sinus node dysfunction, sino-atrial block, and features of Brugada syndrome (see Section III) that occur concomitantly or in isolation in a single patient and family members even in the presence of an identical genetic cause. In non-isolated forms of CCD, congenital heart disease (e.g., atrial septal defect, congenital AV block), cardiomyopathy (e.g., dilated cardiomyopathy, as a lamin or cytoskeleton disorder; see Section IX), or extra-cardiac manifestation is present.

No systematic clinical data are available on the age of onset and course of symptoms in genetically affected individuals. Based on long-term observations in large CCD families, unaffected individuals beyond the age of 40 years can be differentiated from SCN5A-CCD mutation-positive subjects based upon ECG criteria as most older mutation-positive subjects exhibit prolonged PR and QRS intervals.

**Diagnostic Implications of CCD Genetic Testing**

When genetically mediated, the majority of CCD patients have an autosomal dominant mode of inheritance. Recessive or sporadic forms are rare. In isolated CCD, mutations in the gene encoding for the cardiac sodium channel (SCN5A) cause the majority of familial CCD, while mutations in the gene for the beta subunit (SCN1B) are single reports. Recently, mutations in the transient receptor potential cation channel, subfamily M, member 4 (TRPM4) Ca\(^{2+}\)-activated cation channel gene were reported in patients with progressive CCD. These are estimated to account for a significant portion of inherited forms of RBBB (25%) or AV block (10%). Taken together, tiered genetic testing in patients with isolated CCD should comprise the SCN5A and TRPM4 genes.

The relative portion of the identified genes within CCD families is not known. In idiopathic sinus node dysfunction (SND), mutations in the cardiac pacemaker channel gene HCN4 and in sodium channel genes can be identified in an unknown portion. However, because non-genetic causes appear more frequently in idiopathic SND, genetic testing for idiopathic SND should be considered on an individual basis.

When CCD is accompanied by the presence of concomitant congenital heart disease like atrial septal defects, mutations in cardiac transcription factor genes (NKX2.5 or GATA4) are more likely. In absence of congenital heart disease, CCD also may precede left ventricular contractile dysfunction and development of dilated cardiomyopathy. This constellation typically is found in patients with laminopathies (LMNA gene), desmin-related myopathies (DES gene), or muscular dystrophies (e.g., EMD gene), and musculoskeletal and other abnormalities also can be found. Pleiotropic (tissue-spe-
cific) phenotypic expression of mutations may have an individual and age-dependent onset. Within larger sets, 74% of DES mutation-positive subjects have cardiologi- cal signs (in 22% isolated), in the majority a dilated cardiomyopathy and atrioventricular conduction delay (60%).115 LMNA mutation-positive subjects share a sim- ilar pattern.116,117 In a few CCD families, SCN5A gene mutations or a reduced SCN5A protein expression may be associated with the development of heart failure and dilated cardiomyopathy.118–121 Taken together, tiered ge- netic testing for patients with CCD and congenital heart disease or cardiomyopathies is useful because other cardiac and non-cardiac disease features may be present or may develop; individual genes should be considered after discussion of clinical features with an experienced cardio- genetic center.

Index Cases
The diagnosis of a CCD in an index patient is a clinical one that requires an appropriate, ideally 12-lead ECG recording. In the majority of index cases, presence of congenital heart disease and cardiomyopathy must be investigated by echo- cardiography. Additional imaging studies including cardiac MRI may be considered. Early-onset CCD in the absence of structural heart disease should prompt consideration of CCD genetic testing, especially if a positive family history of conduction abnormalities and pacemaker implants is identified.

For the major genes associated with CCD, specialized cardiogenetic services have established a comprehensive testing panel. More than 20 SCN5A mutations are known, among them 75% missense mutations with a predicted full- length protein (see www.fsm.it/cardmoc/) and a randomly appearing distribution of the mutant site within the sodium channel protein. Despite the evidence that a loss of function is the key mechanism in sodium channel-related CCD, non- sense mutations are not as frequent as missense mutations. In addition, non-synonymous SCN5A gene variation is a frequent and ethnic-specific observation122 without impact on CCD. It is unclear as to whether a mutation in SCN5A resulting in NaV1.5 loss-of-function will yield a phenotype of BrS or CCD or an overlap syndrome with elements of both. Taken together, the identification of a CCD mutation confirms not only a clinical or suspected diagnosis of CCD but also allows its classification as a genetic (and potentially heritable) disease.

Family Screening
Cascade family screening is useful in families with mutation-positive CCD. When a clinical diagnosis of CCD is established in an index case, whether isolated or in conjunc- tion with congenital heart disease, a careful clinical investi- nation of first-degree family members, even of those appearing unaffected, is necessary. Genotyping of family relatives is done after mutation identification in the index cases and may be useful to exclude presence or develop- ment of CCD. Due to the age-dependent disease mani- festation, asymptomatic children in the first decade of life may not be genetically investigated with the same impetus as family members in higher decades. Taken together, a clinical and genetic evaluation of family members is generally recommended to detect inherited forms of CCD disease and of associated, other cardiac and non-cardiac disease fea- tures.

Prognostic and Therapeutic Implications of CCD Genetic Testing
There is no genotype-based risk stratification for patients with CCD. Some mutations may be associated with development of heart failure and/or extracardiac features, such as myopathic features, that can be followed and treated after having CCD classified as a genetic entity.

Asymptomatic family members who are positive for the family’s CCD-associated mutation should be regularly and prospectively followed for development of CCD-related symptoms, deterioration of cardiac conduction, and begin- ning of heart failure. In addition, medications with conduction slowing properties (e.g., antidepressants, antiarrhyth- mics) should be restricted, and fever, an aggravating trigger in individuals with sodium channel gene mutations, should be preemptively and symptomatically treated. Because there is no direct prognostic impact of a gene mutation, pace- maker implantations follow the national or internationally accepted indications123 independent of genetic status.

V. STATE OF GENETIC TESTING FOR SHORT QT SYNDROME (SQTS)
Expert Consensus Recommendations
1. Comprehensive or SQT1-3 (KCNH2, KCNQ1, and KCNJ2) targeted SQTS genetic testing may be consid- ered for any patient in whom a cardiologist has estab- lished a strong clinical index of suspicion for SQTS based on examination of the patient’s clinical history, family history, and electrocardiographic phenotype.
2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the SQTS-causative mutation in an index case.

The short QT syndrome (SQTS) was described originally in 2000124 as a new electrocardiographic pattern associated with atrial fibrillation and/or sudden cardiac death in the structurally normal heart. The characteristic sign for the disease is the presence of a very short QT interval on ECG, which may be accompanied by peaked T waves especially in the precordial leads. The age at onset of clinical manifesta- tions may be extremely young, with reports of malignant forms being responsible for even neonatal sudden car- diac death, sometimes attributed to SIDS.125,126 The severity of the clinical manifestations of SQTS is highly variable, ranging from asymptomatic to atrial fibrillation, from recurrent syncope to sudden death.

The clinical diagnosis of SQTS remains a challenge, especially due to the difficulty of defining a newly described disease and the tendency of early reports to emphasize the
most extreme of disease phenotype. An absolute cut-off of abbreviated QTc interval for diagnostic consideration of SQTS has not been clearly defined. Epidemiologic data from a middle-aged Finnish population involving 10,822 men and women indicated that 97.5% of males had a QTc greater than 348 ms, while a value of 364 ms was identified for females. Other large studies involving American, Japanese, and Swiss subjects have produced similar findings with the mean QTc generally 400 to 410 ms and values 2 standard deviations below the mean approximating 350 ms in males and 365 ms in females. However, SQTS genetic testing should not be pursued only because the QTc value is less than the lower 2.5th percentile. Instead, QTc values less than the 0.1 percentile would be more appropriate before ever considering SQTS genetic testing in the absence of symptoms.

Similar to LQTS, QTc overlap between SQTS and healthy controls exists, requiring the need for further diagnostic criteria to clarify diagnosis. A diagnostic scorecard for identifying low probability, intermediate probability and high probability cases has been published recently. Therapeutic options include the implantation of a defibrillator in cases of SCD or unexplained syncope meeting criteria for SQTS. Management of asymptomatic individuals or those with atrial fibrillation without ventricular arrhythmias remains uncertain. When a defibrillator is not recommended, the use of quinidine as primary therapy has been advocated due to its effect in prolonging the QT interval. However, longer follow-up is required to reach conclusions regarding efficacy of this approach.

Diagnostic Implications of SQTS Genetic Testing
SQTS is an autosomal dominant disease and genetically heterogeneous. Three SQTS-susceptibility potassium channel genes have been identified: KCNH2 (SQT1), KCNQ1 (SQT2), and KCNJ2 (SQT3). Mutations in these genes yield a gain-of-function to their encoded potassium channel. Clinical cases describing a type 1 Brugada ECG pattern and associated with short QT-intervals and genetic signatures have been frequently described and proposed to represent sub-types of SQTS. However, as these cases may be readily recognized as BrS, invoking a second or alternative diagnosis of SQTS does not appear to be unique to individual families and thus are rare causes of the arrhythmia.

Prognostic and Therapeutic Implications of SQTS Genetic Testing
No genotype–phenotype correlation studies have been performed due to the few families available. However, it is clear that the identical QT-associated mutation may yield a varied phenotype. This indicates that patient-oriented, not family-oriented, clinical decisions must be made. Treatment decisions in high probability cases of SQTS are not influenced by genetic findings.

VI. STATE OF GENETIC TESTING FOR ATRIAL FIBRILLATION

Expert Consensus Recommendations
1. Genetic testing is not indicated for atrial fibrillation at this time.
2. SNP genotyping in general and SNP rs2200733 genotyping at the 4q25 locus for AF is not indicated at this time based on the limited outcome data currently available.

Atrial fibrillation (AF) is the most common sustained arrhythmia and its prevalence is increasing. AF is associated with an increased risk of stroke, heart failure, dementia, and death. Symptoms of AF include palpitations, fatigue, dyspnea on exertion, and chest pain, though many patients are found to have AF incidentally. Numerous risk factors for AF have been described, including hypertension, heart failure, and valve disease. AF has a genetic basis, as a family history of AF is associated with a two-fold risk of the disease. If a family member is affected by AF before age 60, the relative risk increases to 4.7.

Diagnostic Implications of AF Genetic Testing
Mutations have been described in families with autosomal dominant AF including KCNQ1, KCNJ2, KCNE2, SCN5A, KCN5A, NPPA. Numerous other ion channel genes have been implicated in sporadic forms of AF, most notably the cardiac connexin genes GJA1 and GJA5, the genes encoding connexin 40 and connexin 43. Despite the number of genes related to AF, the mutations identified appear to be unique to individual families and thus are rare causes of the arrhythmia.

Prognostic and Therapeutic Implications of AF Genetic Testing
There is no prognostic or therapeutic impact derived from an AF genetic test result.

VII. STATE OF GENETIC TESTING FOR HYPERTROPHIC CARDIOMYOPATHY (HCM)

Expert Consensus Recommendations
1. Comprehensive or targeted (MYBPC3, MYH7, TNNI3, TNNT2, TPM1) HCM genetic testing is recommended for any patient in whom a cardiologist has established a clinical diagnosis of HCM based on examination of the
patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.

2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the HCM-causative mutation in an index case.

Hypertrophic cardiomyopathy (HCM) is a common disorder (affecting 1 in 500 people) characterized by unexplained cardiac hypertrophy, myocyte disarray, and fibrosis. HCM is inherited as an autosomal dominant trait in the majority of adult patients with typical features; de novo mutations are seen but are uncommon. However, the proportion of familial disease is lower in older patients and/or those with non-classical features. As with other inherited cardiomyopathies, HCM shows marked phenotypic variability, even within families. Penetration (i.e., the proportion of mutation-positive subjects who have clinically detectable disease) increases with age but remains incomplete. The risk of sudden death is low in patients with no clinical risk factors but is sufficient in those with one or more risk factors to justify consideration of ICD implantation. Although the absolute risk of SCD may be lower in HCM than some other conditions considered in these guidelines, its high prevalence makes HCM one of the most frequently identified causes of SCD. As most individuals with HCM are asymptomatic and sudden death may be unheralded, cascade screening in families offers the best potential for prevention. Because clinical features can sometimes be mild or uncertain, genetic testing may provide the most effective means of identifying at-risk individuals.

Diagnostic Implications of HCM Genetic Testing

Summary of Common HCM Genes (Table 2)

HCM was termed a “disease of the sarcomere” when the first three disease genes identified were found to encode components of the contractile apparatus. Mutations in at least eight sarcomere protein genes have been shown to cause HCM. Disease-causing mutations in MYH7, encoding beta-myosin heavy chain, and MYBPC3, encoding cardiac myosin binding protein-C, are the most common, each accounting for one quarter to one third of all cases, with the remaining HCM genes each contributing 1% to 5% or less. Within each gene, most individual mutations are rare and indeed are frequently unique to single families. Some founder mutations are seen; as expected these are typically variants associated with less severe disease.

Further disease genes have been implicated in HCM, albeit with less robust evidence. Mutations in CSRP3, encoding muscle LIM protein, are supported by good evidence including co-segregation and mutations in ACTN2 (alpha-actinin 2) also showing some evidence of co-segregation. Further rare variants have been described in candidate gene studies of TCAP (T-cap protein), ANKRD1 (CARP), and JPH2 (junctophilin).

A number of phenocopies of HCM present with apparently similar cardiac features in the setting of different inheritance patterns and/or systemic features. These include the compound phenotype of HCM with Wolff-Parkinson-White syndrome and conduction abnormalities caused by mutations in PRKAG2, Fabry disease and Danon disease, mitochondrial DNA mutations and Noonan syndrome. In addition, there can be genetic overlap between HCM and left ventricular non-compaction (LVNC). These disorders should be considered in familial evaluation and, where appropriate, in genetic testing strategies.

Phenotypic correlations with the underlying HCM disease gene are of limited utility for managing patients; quantitative differences exist but there is substantial overlap between different disease gene groups, and exceptions are common. MYH7 alleles usually are associated with relatively robust clinical disease expression. MYBPC3 mutations have been associated with later onset disease, but once HCM is manifest the usual complication rates apply. In a significant proportion of families with TNNT2 mutations, the phenotype is of minor hypertrophy but substantial arrhythmia risk, but not all TNNT2 mutations behave this way. Allelic heterogeneity compounds the interpretation further, as the rarity of individual mutations usually means that insufficient clinical data are available to reliably characterize a given variant.

The diagnostic yield of sarcomere gene testing (e.g., comprising up to 9 genes) in clinical cases of familial HCM is typically approximately 60%; the yield depends upon patient selection, falling to approximately 30% in sporadic disease. Approximately 5% of cases have two or more variants (compound or double heterozygotes) though in many cases at least one of the variants is of uncertain significance. It is not known if index cases with a negative HCM genetic test have HCM-causing mutations in unexplored regions within the known HCM genes, in undiscovered genes or, instead, do not have a Mendelian cardiomyopathy. The absence of large families mapping to non-sarcomere loci favors the latter explanation.

Index Cases

Genetic testing is recommended for patients with a firm clinical diagnosis of HCM in which mutation-specific confirmatory testing would benefit family members and potentially other relatives. This will include (a) families with a history of SCD (where risk stratification will be skewed toward a higher risk profile with greater likelihood of active intervention in those found to be affected); (b) families in which multiple relatives are at risk who would otherwise need clinical evaluation; and (c) families in which clinical diagnosis is difficult, including those in which individuals have had clinical complications from HCM despite only mild hypertrophy. Similarly, genetic analysis of post mortem samples should be considered in instances of SCD where HCM was not previously known in the family.

Genetic testing is not recommended for diagnosis of HCM in patients with non-diagnostic clinical features outside the setting of expert clinical and detailed family assessment (e.g., to evaluate an athlete’s heart). The absence of a sarcomere mutation cannot rule out familial HCM and variants of uncertain significance are a more frequent problem.
in those with lower clinical pre-test probability of a pathogenic sarcomere mutation. For the same reason, population genetic screening for HCM is not advisable.

Family Screening
When a presumed pathogenetic mutation is identified in a clinically affected index case, testing **is recommended** for all first-degree relatives (i.e., offspring, siblings, parents). Such mutation-specific genetic testing of the relatives (i.e., cascade screening) may have particular advantages over clinical screening of family members for HCM, as EKG/ECG or echo-cardiographic abnormalities may be absent or subtle, or develop late in life. Genetic screening in families with a known mutation is cost-effective, allowing half of the relatives tested to be discharged without need for clinical investigations or long-term follow-up.\textsuperscript{172} Because HCM can confer significant risks even in young children, cascade genetic testing often involves children and must be undertaken with attention to counseling, education, and psychological assessment.

Prognostic Implications of HCM Genetic Testing
Knowledge of the underlying gene and mutation has a limited role in risk assessment and management of the individual patient, which instead is based largely on clinical risk factors.\textsuperscript{173} However, validated clinical risk factors include a family history of SCD,\textsuperscript{173} suggesting that with greater knowledge genotype–phenotype correlations ought to be useful in HCM. For example, patients with features of HCM but without pathogenic sarcomere mutations have a lower likelihood of a positive family history and, on average, a milder phenotype\textsuperscript{174}; thus, a negative genetic test may be of prognostic significance. There are only a few specific mutations that might carry a role in risk assessment and management of the individual patient, which instead is based largely on clinical risk factors.\textsuperscript{173} However, validated clinical risk factors include a family history of SCD,\textsuperscript{173} suggesting that with greater knowledge genotype–phenotype correlations ought to be useful in HCM. For example, patients with features of HCM but without pathogenic sarcomere mutations have a lower likelihood of a positive family history and, on average, a milder phenotype\textsuperscript{174}; thus, a negative genetic test may be of prognostic significance. There are only a few specific mutations that might carry a

Therapeutic Implications of HCM Genetic Testing
Within typical, sarcomeric HCM, no HCM mutation-specific therapeutic implications exist, as therapy in HCM is not disease modifying and treatment response is not influenced by mutation type. However, experimental studies and small phase II clinical trials of interventions (including diltiazem and angiotensin receptor/aldosterone blockade) designed as disease modifying show promise\textsuperscript{176–178}; there is growing interest in efforts aimed at preventing the development of overt HCM in mutation-positive subjects.\textsuperscript{175} Genotyping to identify such preclinical patients is expected to remain a research area for now but may enable genetically directed prophylactic pharmacotherapy in the future. However, for a small subset of patients with apparent HCM, genetic testing may reveal phenocopies of HCM (such as GLA-HCM or LAMP2-HCM) in individual patients and their families. Such genetic test results may have direct therapeutic implications including enzyme-replacement therapy in GLA-HCM (Fabry disease) and early transplantation in LAMP2-HCM (Danon disease).

VIII. STATE OF GENETIC TESTING FOR ARRHYTHMOGENIC CARDIOMYOPATHY (ACM)/ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC)

Expert Consensus Recommendations

1. Comprehensive or targeted (DSC2, DSG2, DSP, JUP, PKP2, and TMEM43) ACM/ARVC genetic testing can be useful for patients satisfying task force diagnostic criteria for ACM/ARVC.

2. Genetic testing may be considered for patients with possible ACM/ARVC (1 major or 2 minor criteria) according to the 2010 task force criteria.

3. Genetic testing is not recommended for patients with only a single minor criterion according to the 2010 task force criteria.

4. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of the ACM/ARVC-causative mutation in an index case.

Arrhythmogenic cardiomyopathy (ACM) is a progressive, heritable myocardial disorder that is a leading cause of ventricular arrhythmia and sudden cardiac death (SCD) in people age \(\leq 35\) years.\textsuperscript{180,181} The disease may involve either or both ventricles, but is most well recognized in its classic subtype with right-sided preponderance, arrhythmogenic right ventricular cardiomyopathy (ARVC).\textsuperscript{182,183} Clinical diagnosis is based on demonstration of characteristic ECG, arrhythmic, structural, and/or histological abnormalities.\textsuperscript{182,184} A confirmed family history and/or the presence of a definite or probable disease-causing mutation also contributes to diagnosis. Morphological abnormalities may resemble dilated cardiomyopathy, but the clinical presentation typically is with arrhythmia rather than heart failure manifestations. Classification of the disease bridges the gap between cardiomyopathies and inherited arrhythmia syndromes.\textsuperscript{185} The early, “concealed” phase is characterized by propensity toward ventricular arrhythmia in the setting of preserved morphology, histology, and ventricular function. As the disease progresses, myocyte loss, inflammation, and fibroadiposis become evident. Structural abnormalities range from regional wall motion abnormalities, ventricular aneurysms, and increased trabeculation to global ventricular dilation and dysfunction.\textsuperscript{186} Ventricular arrhythmia remains the most common clinical manifestation until the advanced stage of the disease, when a minority of individuals develop heart failure.\textsuperscript{187,188}

ACM/ARVC is most commonly transmitted as an autosomal dominant trait, although incomplete penetrance coupled with variable and age-dependent expression may obscure Mendelian inheritance patterns.\textsuperscript{189–191} Autosomal recessive forms are rare but recognized, most prominently in the cardiocutaneous syndromes of Naxos and Carvajal.\textsuperscript{192–196} Compound heterozygosity (co-inheritance of different disease alleles of a single gene) and digenic heterozygosity (co-inheritance of disease alleles for two different genes) frequently (up to 10% of the time) are identified,\textsuperscript{197}
and may contribute to the variable penetrance and complexity of disease inheritance in ACM.

**Diagnostic Implications of ACM/ARVC Genetic Testing**

**Summary of the Common ACM/ARVC Genes (see Table 2)**

Most of the genes implicated in ACM/ARVC encode desmosomal proteins (plakoglobin [JUP], desmplakin [DSP], plakophilin-2 [PKP2], desmoglein-2 [DSG2], and desmocollin-2 [DSC2]).

There are isolated reports of causal mutations in extra-desmosomal genes. The S358L mutation in TMEM43 in the Newfoundland founder population causes a fully penetrant, nonclassic form of the disease associated with a high incidence of SCD and heart failure. Mutations in TGFβ3 have been identified in a single family and unrelated index case, but not in other kindreds with linkage to the same chromosomal locus. The cardiac ryanodine receptor (RyR2) has been linked to a distinct clinical entity, ARVC2, which is characterized by juvenile SCD and effort-induced polymorphic ventricular tachycardia.

ARVC2 is clinically and genetically similar to type 1 catecholaminergic polymorphic ventricular tachycardia (CPVT1) and likely represents a CPVT phenocopy rather than true ARVC.

Thirty percent to 70% of cases of ACM/ARVC harbor mutations in one of the implicated desmosomal genes, most of which show marked allelic heterogeneity. Estimates of the success rate of genotyping vary according to cohort location and ethnicity, selection criteria, and the stringency of the standards by which mutations are considered causal. Common haplotypes consistent with founder effects contribute to the 70% reported prevalence of PKP2 mutations among ARVC families in the Netherlands.

In other cohorts, recent studies suggest that many of the PKP2 variants previously linked to ARVC actually are of uncertain pathogenicity. Three previously reported missense variants occur in 0.5% to 1.4% of healthy control subjects. Furthermore, among a series of 38 index cases with PKP2 defects, 9 were compound heterozygotes and 16 were double heterozygotes, with additional rare variants in other desmosomal genes. This suggests that many PKP2 variants are not sufficient per se for clinical disease. Doubt also has been cast on the pathogenicity of certain genetic variants in DSG2, which have been identified in healthy control subjects at frequencies of 0.5%–13.9%. Reports nevertheless indicate that many of the disputed desmosomal gene variants are selectively enriched in cases compared with controls, implying contribution to disease expression.

The genetics of ACM/ARVC may therefore be more complex than previously appreciated, with frequent requirement for more than one “hit” for penetrant disease.

Arrhythmogenic cardiomyopathy behaves as a complex disease in many families, complicating definitive genetic diagnosis. Integration of genetic testing into clinical practice is nonetheless proceeding, with the main applications being confirmatory testing in index cases and cascade screening of families. ACM genetic diagnosis is a moving target, with new pathogenic mutations being discovered, and mutations previously considered pathogenic sometimes being reclassified/denoted to a status of benign or unknown clinical significance as new data emerge. Given the approximate 50% yield of the current generation genetic test for a robust case of ACM and the 16% frequency of rare variants in these same genes among ostensibly healthy volunteers, it is possible that up to one-third of the rare missense variants identified during ACM genetic testing represent false positives. Extreme caution is therefore necessary regarding both obtaining an ACM/ARVC genetic test and interpreting its significance. In particular, it may be prudent to refer a patient with a questionable diagnosis of ACM/ARVC to a specialty center rather than order the genetic test.

**Index Cases**

Confirmatory testing is defined as the use of genotyping to corroborate clinical diagnosis suspicion of disease in an index case. In ACM/ARVC, the appeal of confirmatory testing is strongest among populations with proven founder effects, such as the Netherlands and Newfoundland. Obstacles to this approach in other cohorts are numerous. Frequent “private” mutations necessitate de novo determination of causality, while variants with reduced penetrance and uncertain pathogenicity may nonetheless contribute.

Because the diagnostic yield from screening the known causal genes is limited, failure to identify a mutation does not exclude the disease.

The early stage of ACM/ARVC is described as “concealed” because sentinel clinical abnormalities are lacking. Disease expression may be limited to a single feature common to other disorders, such as right precordial T-wave inversion or ventricular tachycardia of left bundle branch block morphology. Reliable and timely diagnosis is critical, however, because affected individuals may be at risk of SCD and management protocols must be tailored accordingly. In these cases, isolation of a radical variant in a desmosomal gene may be invaluable, while variants of unknown pathogenicity may suggest the need for close observation.

**Family Screening**

The combination of variable penetrance, age-related expression, and unpredictable disease flare-ups complicates evaluation of relatives in ACM. An unremarkable clinical evaluation does not preclude transmission of the disease to children or onset of disease expression in later life, even beyond middle age. Referral centers specializing in familial disease have responded to this dilemma by offering periodic reassessment to first-, second-, and sometimes third-degree relatives. The burden on clinical resources is significant, as is the psychological impact on relatives, who must reconcile themselves to lifelong screening without major prospect of definitive reassurance. The less attractive alternative would entail presumption of gene-negative status among clinically unaffected adults, and accepting that a minority of them or their children may present catastrophically with an arrhythmic event.

Definitive genetic diagnosis in an index case offers an attractive solution by enabling cascade screening of fами-
lies. In a typical family with an autosomal dominant inheritance pattern, approximately half of relatives will test gene-negative, affording them with permanent reassurance and obviating the need to screen their children. Resources then can be targeted to proven ACM mutation-positive subjects, who will require lifelong observation. This scenario, however, is feasible only when the identified mutation is an unequivocal, or at least high-probability, ACM-causative mutation. Given the complexity of the disease phenotype in many families and uncertainties in assessing pathogenicity of variants, caution is justified before discharging relatives with symptoms or borderline clinical abnormalities on the basis of a “negative” gene test.

Prognostic and Therapeutic Implications of ACM/ARVC Gene Testing

The spate of genotype–phenotype studies that followed the isolation of primary mutations in arrhythmic cardiomyopathy has identified few definitive patterns. Left ventricular involvement appears more marked in families with chain-termination mutations and/or desmoplakin disease, while individuals harboring PKP2 variants may have earlier onset of both symptoms and ventricular arrhythmia. Intrafamilial phenotype diversity, however, is prominent. In contrast to HCM, a family history of SCD does not appear to be a key indicator of adverse prognosis in ACM, suggesting that primary mutation analysis is of limited value in risk prediction. Variance component analysis suggests that both genetic and environmental modifiers contribute significantly to varying disease penetrance and phenotypic manifestations, including arrhythmic outcome, between family members who carry a gene mutation in arrhythmic cardiomyopathy. Systematic investigation of genetic background ultimately may carve out a niche for comprehensive genetic profiling in prognostication and management, but attempts to do so are premature.

Ongoing follow-up studies will shed light on disease evolution in the growing cohort of apparently silent mutation-positive subjects. The paucity of data precludes formulation of management guidelines excepting the need for periodic re-evaluation. Animal studies and anecdotal clinical reports suggest that prolonged and intense physical activity, particularly endurance training, may accelerate disease progression. In the absence of large-scale clinical validation, however, prescriptive counseling of mutation-positive/phenotype-negative subjects must be counter-balanced by recognition of individual lifestyle preferences and the benefits of exercise on general and psychological health.

IX. STATE OF GENETIC TESTING FOR DILATED CARDIOMYOPATHY (DCM)

Expert Consensus Recommendations

1. Comprehensive or targeted (LMNA and SCN5A) DCM genetic testing is recommended for patients with DCM and significant cardiac conduction disease (i.e., first, second, or third-degree heart block) and/or a family history of premature unexpected sudden death.

2. Genetic testing can be useful for patients with familial DCM to confirm the diagnosis, to recognize those who are at highest risk of arrhythmia and syndromic features, to facilitate cascade screening within the family, and to help with family planning.

3. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of a DCM-causative mutation in the index case.

Dilated cardiomyopathy (DCM) is characterized by systolic dysfunction and left ventricular enlargement (LVE). Although many different insults to myocardium may cause a phenotype of dilated cardiomyopathy, the term DCM here implies that resulting from genetic cause. Patients who have genetic DCM present as DCM of unknown etiology and are usually assigned a diagnosis of idiopathic dilated cardiomyopathy (IDC) after detectable causes have been excluded. In most cases, no particular phenotypic features differentiate genetic DCM from IDC. Patients presenting with IDC have been shown to have familial DCM (familial dilated cardiomyopathy [FDC]) in 20% to 35% of cases when first-degree relatives are screened clinically (history, exam, ECG, echocardiogram), and as high as 48% if LVE itself is taken as an early sign of DCM. For this reason, clinical screening of family members of an index case presenting with DCM of unknown cause has been recommended. Whether sporadic DCM is principally a genetic disease remains untested in large prospective studies, and the role of genetic testing in sporadic disease remains uncertain.

Diagnostic Implications of DCM Genetic Testing

One goal of genetic testing for DCM is to identify at-risk relatives who host a disease-causing mutation. It should always be integrated into information derived from clinical screening. A genetic test also can help identify the cause of the condition and identify patients who are at highest risk of extra-cardiac features. A negative analysis of a family member in the case of a clearly pathogenic mutation in the index case is reassuring that this disorder will not occur in this family member. It is particularly important in children, allowing them to live a normal life, especially during their youth.

Index Case

DCM arising from genetic cause results principally from rare non-synonymous variants, primarily missense, with occasional nonsense, splice site, or small insertion/deletion variants. Rare variant missense mutations in >30 genes have been implicated. However, none of these genes appears to account for >5% of familial DCM. Recent reviews provide comprehensive DCM gene lists and highlight the broad variety of encoded proteins implicated in the pathogenesis of DCM, including cytoskeletal proteins, myofilament proteins, proteins of the nuclear envelope, and ion channels. The prevalence of larger deletions, dupli-
cations, or rearrangements not discernible by the most common methods of genetic testing is not known.

Most genetic DCM inheritance follows an autosomal dominant pattern, although X-linked, recessive, and mitochondrial patterns of inheritance occur. The sensitivity of genetic testing is estimated at 15% to 25%. This varies regarding the number of genes that are tested and the phenotypic features of the person tested. Those with conduction disease, elevated creatine kinase, and similarly affected family members may have the highest yield of genetic testing (Table 2).

Genetic DCM shows age-dependent penetrance. This means that an individual who carries a disease-causing rare variant is more likely to show a disease phenotype with increasing age, and that a normal phenotypic assessment by echocardiogram and ECG does not exclude the possibility of later onset disease.

The age of onset ranges from early infancy through late adulthood. Variable age of onset within a family carrying the same genetic predisposition to DCM often occurs. DCM also shows variable penetrance—manifestations of the disease can vary by individual, even among family members who all have the same variant, from a very mild case (e.g., minimal systolic dysfunction, minimal LVE) to aggressive, fully developed disease.

In some families, infants present with more aggressive disease than their relatives. Disease onset in young children should be used in a positive manner by allowing the diagnosis to facilitate family clinical screening of first-degree relatives. Also notable, young children may have metabolic and mitochondrial forms of hereditary DCM.

DCM is associated with muscular dystrophy, and any patient with an unknown form of skeletal myopathy should be assessed for associated cardiomyopathy. DCM is most prominently involved in the dystrophinopathies, resulting from mutations in dystrophin, and can lead to Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and X-linked cardiomyopathy (XLCM). DCM also can occur with myotonic dystrophy, myofibrillar myopathy, and many of the limb girdle muscular dystrophies.

Conduction system disease and/or serious, life-threatening arrhythmias with muscular dystrophy, usually but not always associated with DCM, also are prominent with Emery-Dreifuss muscular dystrophy, caused by LMNA or EMD mutations, and in desmin-related myopathies (DRM) that result from DES mutations.225

Family Screening

As a key surrogate to genetic testing and in recognition of the potential heritability of idiopathic DCM, patients with idiopathic DCM should be assessed with at least a 3-generational family history. All first-degree relatives of a patient with idiopathic DCM should be evaluated echocardiographically. Inference regarding arrhythmia risk can be influenced by the results of genetic testing. Individuals with a mutation in LMNA and DES appear to have increased risk of sudden cardiac death.225 Decisions regarding the use of a prophylactic ICD should not depend only on the ejection fraction.221

---

**Prognostic Implications of DCM Genetic Testing**

There is no prognostic role of genetic testing for DCM except for the increased risk of sudden cardiac death in LMNA- and DES-mediated disease.

**Therapeutic Implications of DCM Genetic Testing**

A therapeutic role for DCM genetic testing exists for patients with DCM and prominent cardiac conduction system disease (CCD, also see Section IV) that often stems from mutations in LMNA (Figure 1). Because CCD (e.g., first-, second-, or third-degree heart block) and supra-ventricular arrhythmias commonly precede life-threatening ventricular arrhythmias, early or pre-emptive use of an implantable cardiac defibrillator (rather than a pacemaker) has been advocated prior to the occurrence of life-threatening syncope or sudden cardiac death.221 It is unknown whether early pharmacological treatment of mutation-positive, pre-clinical subjects can prevent or delay manifestation of the disease. Genetic testing also has a therapeutic role for syndromic disease (e.g., muscular dystrophy) with known arrhythmia and/or conduction system disease (e.g., LMNA, DES variants) in terms of possible consideration of a prophylactic PM and/or ICD.

---

**X. STATE OF GENETIC TESTING FOR LEFT VENTRICULAR NONCOMPACTION (LVNC)**

**Expert Consensus Recommendations**

1. LVNC genetic testing can be useful for patients in whom a cardiologist has established a clinical diagnosis of LVNC based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.

2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of an LVNC-causative mutation in the index case.

Left ventricular noncompaction (LVNC) is a recently classified form of inherited cardiomyopathy that is characterized by excessive and unusual trabeculations within the mature left ventricle (LV). LVNC represents a developmental failure of the heart to form fully the compact myocardium during the later stages of cardiac development.226 Clinically and pathologically, LVNC is characterized by a spongy morphological appearance of the myocardium occurring primarily in the LV, with the abnormal trabeculations typically being most evident in the apical and midlateral-inferior portions of the LV.227,228 In addition to the regional presence of prominent trabeculae and intertrabecular recesses in the LV, thickening of the myocardium in two distinct layers composed of compacted and non-compacted myocardium also classically is noted. The ratio of non-compacted versus compacted myocardium is often larger than 2.0 but there is controversy regarding diagnostic imaging criteria.

Patients with LVNC may present with a broad clinical spectrum from asymptomatic to severe heart failure and/or arrhythmias, and may be associated with overlapping features of left ventricular hypertrophy, dilation, restrictive features, or with various forms of congenital heart disease. The myocar-
The clinical diagnosis of LVNC depends on particular expertise and knowledge of disease and imaging modalities, particularly echocardiography and cardiac magnetic resonance imaging (CMR), and is supported by electrocardiographic findings. Due to the low rate of a positive genetic test in index cases, the utility of genetic testing for the definitive diagnosis and care of the index case is of limited use. However, fee-for-service clinical genetic testing is available and is likely to become more useful as the larger percent of disease-causing genes is identified and larger series of patients have been evaluated.

Family Screening

Due to possible X-linked inheritance in some patients, affected male family members may have a more pronounced disease expression and females may have slighter signs of LVNC (or none at all), and thus may serve as transmitters for following generations. Somatic mitochondrial alterations are, in general, not heritable to next generations and require a different clinical and genetic consultation. Due to LVNC’s potential heritability, patients with LVNC should be assessed with at least a 3-generational family history, and all first-degree relatives of a patient with LVNC should be evaluated echocardiographically.

Prognostic and Therapeutic Implications of LVNC Genetic Testing

No genotype–phenotype correlations have been associated with LVNC. Therefore, no prognostic implications can be speculated. The only implication of genetic testing is confirmation of diagnosis and the potential development of disease in mutation-positive members of the family, if tested. Therapy therefore is based completely on phenotypic findings.

No definitive therapeutic role has been established for LVNC genetic testing. Because associated mitochondrial or metabolic disease or syndromes such as Barth syndrome frequently are associated with LVNC, especially in young children, definitive diagnosis can lead to improved symptomatic therapy and improved prognostication in affected patients and family members.

XI. STATE OF GENETIC TESTING FOR RESTRICTIVE CARDIOMYOPATHY (RCM)

Expert Consensus Recommendations

1. RCM genetic testing may be considered for patients in whom a cardiologist has established a clinical index of suspicion for RCM based on examination of the patient’s clinical history, family history, and electrocardiographic/echocardiographic phenotype.

2. Mutation-specific genetic testing is recommended for family members and appropriate relatives following the identification of an RCM-causative mutation in the index case.

Restrictive cardiomyopathy (RCM) is rare. Little has been reported on its prevalence or natural history. This condition is defined by the presence of impaired ventricular filling and diminished diastolic volume with normal or
nearly normal LV wall thickness and ejection fraction.\(^{243}\) RCM often overlaps with dilated or hypertrophic cardiomyopathies, as its definition is more functional than structural.\(^{245}\) It may be classified as primary or infiltrative, and familial forms are commonly recognized in both categories. Primary RCM typically is genetic, though the absence of clearly affected family members may lead to a diagnosis of idiopathic disease. Advances in the recognition of the genetic basis for RCM have led some to call “idiopathic RCM” an anachronistic term.\(^{245}\)

Affected family members help to assign a pattern of inheritance, because autosomal dominant, recessive, X-linked, and matrilineal inheritance all occur with RCM. Endomyocardial biopsies may be performed when there is suspicion of infiltrative or storage disease. Histopathology typically is notable for extensive interstitial fibrosis. Focal fibrosis of the cardiac conduction system may occur, resulting in heart block or conduction system disease.

The concurrent presence of skeletal myopathy should be investigated, as familial RCM often occurs with mild to severe concomitant skeletal muscle involvement.\(^{246}\) Even among asymptomatic affected individuals, mild elevation of the serum creatine kinase (CK) may help to identify involvement of the skeletal muscle and to target clinical genetic testing.

**Diagnostic Implications of RCM Genetic Testing**

Genetic evaluation in familial RCM can be useful to confirm a diagnosis, to anticipate syndromic features that may accompany RCM, to evaluate family members who are at risk of the condition, and for family planning. Syndromic disorders often accompany familial RCM, and clinical genetic testing may facilitate their recognition.

**Summary of Common RCM Genes (Table 2)**

As with other forms of cardiomyopathy, familial RCM is genetically heterogeneous. RCM-associated mutations have been reported in four genes that encode key sarcomeric proteins/myofilaments (MYH7, TNN2, TNN3, and ACTC) and MYH7- and TNN3-mediated RCM may each account for approximately 5% of the disease (Table 2). Mutations in sarcomere genes tend to cause a cardiac-restricted phenotype without skeletal myopathy, though MYH7 mutations altering the C-terminal portion of cardiac myosin heavy chain may involve Laing distal skeletal myopathy.\(^{247}\) Genes encoding the remaining elements of the cardiac sarcomere remain good candidates for familial RCM but have not yet been shown to cause this particular phenotype.

**Index Cases**

The likelihood of finding a mutation in RCM can be inferred from manuscripts with genetic characterization of small cohorts. In a series of 12 children with RCM (mean age 5.1 years) who had testing of 8 sarcomere genes and DES, heterozygous sarcomere mutations were reported in four of the children, two of which were de novo.\(^{248}\) No mutations were identified in DES among this cohort. In another series of 15 index cases with RCM who had testing of five sarcomere genes, mutations were found in eight of them.\(^{249}\)

Inherited storage disorders, such as hemochromatosis or the glycogen storage diseases, can cause cardiomyopathy, and RCM is a common phenotypic manifestation.\(^{243}\) Familial amyloidosis is a disorder of misfolded protein with pathologic deposition in many organs, though the pathologic amyloid deposition sometimes is present only in the heart. Although there are several genes in which mutations have been reported to cause amyloidosis, familial cardiac amyloidosis is most commonly caused by mutations in TTR, which encodes transthyretin.\(^{250}\) Although transthyretin amyloidosis occurs without race or gender predilection, certain TTR mutations are more common among specific ethnicities. For instance, approximately 3.5% of African-Americans harbor the TTR mutation Val122Ile.\(^{251}\)

Noonan syndrome is a genetically and phenotypically heterogeneous disorder characterized by short stature, characteristic facial features, webbed neck, and hypertrophic or restrictive cardiomyopathy.\(^{252}\) Approximately 50% of individuals diagnosed with Noonan syndrome have a mutation in PTPN11.\(^{253}\) However, Noonan syndrome with either HCM or RCM is seldom PTPN11 positive.\(^{254}\) Other Noonan syndrome susceptibility genes include SOS1, KRAS, RAF1, SHOC2, and NRAS. In one study, mild abnormalities on the ECG were present among 42 of 84 (50%) affected individuals, including left axis deviation, small R waves in the left precordial leads, and abnormal Q waves.\(^{255}\) The reduced prevalence of cardiomyopathy among individuals with a PTPN11 mutation (6%) is balanced by the increased likelihood of finding cardiomyopathy when a RAF1 mutation is present (95%).\(^{256}\) Accordingly, testing with a comprehensive Noonan gene panel is optimal in the setting of Noonan syndrome with cardiomyopathy.

**Family Screening**

As compared with other forms of cardiomyopathy, RCM is difficult to recognize in early stages because the heart does not become structurally dilated or thickened, and mild Doppler abnormalities can occur with hypertension, coronary atherosclerosis, or age. Therefore, a clear pathogenic mutation in an unequivocally affected family member can help in screening family members who are at risk or those who have borderline features suggesting familial RCM. Although not as heritable/familial as DCM and LVNC, patients with idiopathic RCM should be assessed with at least a 3-generational family history, and all first-degree relatives of a patient with idiopathic RCM should be evaluated echocardiographically.

**Prognostic Implications of RCM Genetic Testing**

There is no prognostic role of the genetic test result for the patients with isolated RCM. However, a genetic test that indicates a predisposition to a syndromic disorder such as TTR-amyloidosis can be useful. The use of genetic testing to determine prognostic information is likely best established for family members who are at risk of familial RCM.
Therapeutic Implications of RCM Genetic Testing

While direct therapeutic application of a genetic test result for RCM has not been definitively demonstrated, such results may impact the assessment of arrhythmia. The increased likelihood for arrhythmia associated with mutations in TNNT2, DES, or LMNA may alter one’s approach to phenotypic arrhythmia assessment, though specific genotype-phenotype correlations may not be discernible. For disorders with multi-system involvement, recognition of an underlying syndrome that results in restrictive cardiac physiology can lead to disease-specific therapy, such as transplantation for TTR-amyloidosis or replacement enzyme infusions for some storage diseases. Finally, mutations in non-sarcomere genes can cause RCM, often accompanied by skeletal myopathy and cardiac conduction disease. The combination of RCM with elevated serum creatine kinase suggests a mutation in genes encoding desmin (DES) or lamin A/C (LMNA). Because these are associated with relatively high rates of sudden cardiac death, RCM secondary to DES or LMNA should prompt consideration of a prophylactic ICD, particularly in the setting of AV block or bundle branch block.229,230

XII. STATE OF GENETIC TESTING FOR OUT-OF-HOSPITAL CARDIAC ARREST SURVIVORS

Expert Consensus Recommendations

1. In the survivor of an Unexplained Out-of-Hospital Cardiac Arrest, genetic testing should be guided by the results of medical evaluation and is used for the primary purpose of screening at-risk family members for subclinical disease.

2. Routine genetic testing, in the absence of a clinical index of suspicion for a specific cardiomyopathy or channelopathy, is not indicated for the survivor of an Unexplained Out-of-Hospital Cardiac Arrest.

Out-of-hospital cardiac arrest (OHCA) occurs most commonly in the context of underlying structural heart disease. In older individuals (age >40 years), pre-existing coronary disease remains the most common etiology, while in younger cases, HCM and ACM/ARVC are frequently detected.257,258 These common conditions may be readily diagnosed in survivors of OHCA by coronary angiography and cardiac imaging studies, and in the case of HCM and ACM/ARVC, appropriate genetic evaluation and screening of first-degree relatives pursued (see Sections VII and VIII).

In the absence of evident structural heart disease despite careful evaluation of previous medical records or based on autopsy data, a broad differential diagnosis exists. Evaluations should seek to detect subclinical structural disease, including ACM/ARVC or cardiac sarcoidosis.259,260 Primary electrical diseases secondary to cardiac ion channel disorders may account for up to 25% of cases, including LQTS, CPVT, BrS, SQTS, and early repolarization syndrome (ERS).257,261 The latter has been described recently and may represent a previously unrecognized underlying condition in survivors of OHCA.262

Although most survivors of OHCA may reasonably receive an implantable cardioverter-defibrillator (ICD), arriving at a diagnosis for the event is necessary to minimize the risk of arrhythmia recurrences and enable appropriate evaluation of family members who may be at risk of an inheritable disorder. Determining a diagnosis begins with a systematic clinical evaluation. Subsequently, targeted genetic testing may be considered for the purpose of diagnostic confirmation and family screening.

Clinical Evaluation

A review of the circumstances of the event may provide insight into the etiology. Cardiac arrest during exercise or sympathetic activation may be consistent with either LQT1 or CPVT1, while events secondary to auditory stimuli might suggest LQT2. Previously recognized seizures or cardiac arrest during sleep may be characteristic of BrS or LQT3. Specific family details, including a family history of neuromuscular disease, early pacemaker implantation, or unexplained heart failure, may prioritize investigational pathways to examine and diagnoses to be excluded, e.g., muscular dystrophy, storage diseases, or laminopathies, all of which may be associated with risk of cardiac arrhythmias.

Clinical testing includes resting ECG (and potentially signal-averaged ECG), exercise testing, telemetry/Holter monitoring, echocardiography, and cardiac magnetic resonance imaging. Coronary angiography is usually performed in adults. Provocative adrenergic and sodium channel blocker infusion should be considered for the potential unmasking of latent LQTS and BrS, respectively.262 Caution is advised in reaching precipitous conclusions of either LQTS, BrS, or ERS based on early post-arrest ECGs, which commonly demonstrate either prolonged QT interval secondary to a number of physiological factors or J wave/Brugada ECG pattern changes secondary to therapeutic hypothermia and often resolves over a number of days. Overall, comprehensive clinical testing performed in consultation with specialized arrhythmia clinics may yield a clinical diagnosis in more than 50% of apparent unexplained cardiac arrests.

Role of Genetic Testing in OHCA

When a diagnosis is evident or suspected, genetic testing of the proband generally is recommended to enable cascade screening of family members. In almost all forms of inheritable cardiomyopathies and primary electrical disorders, incomplete or provocable (e.g., medications) disease penetrance is common, necessitating genetic testing in addition to clinical assessment of family members. A “shotgun” genetic testing approach should be avoided in survivors of unexplained cardiac arrest to minimize costs and avoid issues when uncertain genetic findings must be interpreted for family members in the absence of a correlating disease phenotype. Among patients of Dutch ancestry who are clas-
3. Mutation-specific genetic testing is recommended if postmortem genetic testing were performed routinely, it is estimated that 25% to 35% of SUD cases from age 1 to 35 years and up to 15% of SIDS cases may be due to mutation(s) in one of the known channelopathy-associated genes. Intense cardiac testing of the SUD decedent’s living first-degree relatives provides a similar estimate of approximately 25% to 35% of those families being diagnosed with a heritable arrhythmia syndrome.

Family Screening

The identification of a cause of death in a SUD or SIDS case has important implications for the psychosocial welfare of relatives, as it may provide comfort for the family wondering why their young son or daughter has died. Second, there are implications for living relatives, who may be at risk of developing the same disease. Cascade genetic testing in at-risk relatives is an important next step, often performed concurrently with clinical evaluation, with the goal to diagnose other family members who may have the same disease. This forms the foundation for appropriate prevention strategies in family members who possess the gene mutation and/or have clinical features of the disease. For many of the cardiac channelopathies that are potentially diagnosed by postmortem genetic testing, the decedent’s genetic test results may influence directly the treatment of his/her living relatives in the exact same manner detailed for relatives of a living, mutation-positive index case in Sections I to III.

It has not been determined whether it would be more cost-effective to commence the evaluation of SUD among the living members with a cardiac channelopathy-focused molecular autopsy/postmortem genetic test of the decedent, or by clinically examining all first-degree relatives. Appropriate cardiac evaluation is recommended for all first-degree relatives of a SUDS case. However, considering the litany of tests that usually are performed on the living first-degree family members following such a SUD, the estimated 35% yield of a channelopathic explanation in the decedent may make the cardiac channel molecular autopsy the prudent place to start. Nevertheless, impediments to postmortem genetic testing for SUD include lack of reimbursement among third-party payers and lack of uniform standard operating procedures for the retention of material that would permit a comprehensive postmortem genetic test, such as blood in EDTA, blood spot cards, or frozen tissue. Implementation of these procedures will require collaborative...
efforts with organizations that represent medical examiners and forensic pathologists, such as the National Association of Medical Examiners in the United States, to ensure collection and retention of appropriate material that would permit a molecular autopsy if desired. Postmortem genetic testing of every SIDS case, with its estimated 10%–15% yield for LQTS, CPVT, and BrS, may be more difficult to justify from a cost-effectiveness perspective. Genetic testing may have a higher yield in certain age groups (e.g., infants age less than 2 months, infants 4 to 12 months). Instead, a screening 12-lead ECG of such an infant’s parents and siblings may be appropriate.

**Prognostic and Therapeutic Implications of SUDS/SIDS Genetic Testing**

Clinical and genetic screening of relatives of a SUD case provide an important opportunity to identify new at-risk family members and initiate management strategies. These treatment strategies are based on the individual diseases outlined in accompanying guidelines.

**Appendix 1 Glossary of Terms Related to Genetic Testing**

**Allele:** Reciprocal forms of genetic information at a specific locus (location) along the genome. An allele can refer to a segment of DNA or even a single nucleotide. The normal version of genetic information is often considered the “wild-type” or “normal” allele. The vast majority of the human genome represents a single version of genetic information.

**Autosomal Dominant:** The situation in which the disease can be expressed even when just one chromosome harbors the mutation.

**Autosomal Recessive:** The situation in which the disease is expressed only when both chromosomes of a pair are abnormal.

**Cascade Testing:** Procedure whereby all first-degree relatives of a genotype-positive index case are tested in concentric circles of relatedness. If one of the family members is genotype positive, all his/her first-degree relatives should be tested continuing this process following each genotype-positive family member.

**Compound Heterozygosity:** An individual who has two different mutant alleles at a particular locus, one on each chromosome of a pair; usually refers to individuals affected with an autosomal recessive disorder (from GeneTests).

**Copy Number Variation (CNV):** The situation in which the number of copies of a gene or other DNA sequence differs between individuals.

**Digenic Heterozygosity:** An individual with two different mutations in two different disease-associated genes, a “second hit” contributing to disease phenotype.

**Disease-causing Mutation:** A DNA sequence variation that represents an abnormal allele and is not found in the normal healthy population but exists only in the disease population and produces a functionally abnormal product.

**Disease-Associated Mutation**

- **Disease-Associated Mutation – Somatic:** Variants/mutations are said to be somatic if they occur in cells other than gametes. Somatic mutations cannot be transmitted to offspring.
- **Disease-Associated Mutation – Missense:** A single nucleotide substitution resulting in a substitution of an amino acid for a stop codon.
- **Disease-Associated Mutation – Nonsense:** A single nucleotide substitution resulting in a stop codon.

- **Disease-Associated Mutation – Deletion/Insertion:** The removal (deletion) or addition (insertion) of nucleotides to the transcript that can be as small as a single nucleotide insertion/deletion or as large as several hundreds to thousands of nucleotides in length.

**Disease: A genetic defect that results in the exchange of a normal amino acid in the protein for a different one.**

**Disease Causing: A DNA sequence variation that represents an abnormal allele and is not found in the normal healthy population but exists only in the disease population and produces a functionally abnormal product.**

**Dominant:** The situation in which the disease results from a single mutant allele.

**Expressivity:** The level of expression of the phenotype, and when the manifestations of the phenotype in individuals who have the same genotype are diverse, the phenotype is said to exhibit variable expressivity.

**First-Degree Relative:** A blood relative who is a person’s parent, sibling, or child.

**Founder Mutation:** The occurrence of a particular gene mutation at increased frequencies within a given population due to its presence in a small isolated group of ancestors that directly gave rise to the current population.

**Germline:** Heritable change in the genetic makeup of a germ cell (sperm or ovum) that when transmitted to an offspring is incorporated into every cell in the body.

**In-Frame Insertion/Deletion:** In-frame insertions and deletions occur when a multiple of three nucleotides is affected and result in a single or multiple amino acids being removed or added without affecting the remainder of the transcript.

**In Frame:** A configuration that maintains the translation reading frame.

**Missense:** A single nucleotide substitution that results in the exchange of a normal amino acid in the protein for a different one.

**Nonsense:** A single nucleotide substitution resulting in a stop codon.

**Penetrance:** The likelihood that a gene mutation will have any expression at all. In the situation in which the frequency of phenotypic expression is less than 100%, the genetic defect is said to be associated with reduced or incomplete penetrance.
Phenocopy: An individual who manifests the same phenotype (trait) as other individuals of a particular genotype but does not possess this genotype himself/herself.

Phenotype: A person’s observed clinical expression of disease in terms of a morphological, biochemical, or molecular trait.

Polymorphism: Normal variations at distinct loci in the DNA sequence. The vast majority of the human genome represents a single version of genetic information. The DNA from one person is mostly made up of the same exact nucleotide sequence as another person. However, there are many small sections of sequence or even single nucleotides that differ from one individual to another.

Single Nucleotide Polymorphism (SNP): A single nucleotide substitution that occurs with a measurable frequency (i.e., >0.5% allelic frequency) among a particular ethnic population(s).

SNP – Nonsynonymous: A single nucleotide substitution whereby the altered codon encodes for a different amino acid or terminates further protein assembly (i.e., introduces a premature stop codon).

SNP – Synonymous: A single nucleotide substitution occurring in the coding region (exon), whereby the new codon still specifies the same amino acid.

Variant of Uncertain Significance (VUS): A mutation or genetic variation with uncertain clinical significance.

---

Appendix 2  Author Disclosures

<table>
<thead>
<tr>
<th>Authors</th>
<th>Consultant Fees/Honoraria</th>
<th>Speaker’s Bureau</th>
<th>Research Grant</th>
<th>Fellowship Support</th>
<th>Board Mbr/Stock Options/Partner</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ackerman, MD, PhD</td>
<td>Biotronik</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Transgenomic (FAMILION)—Royalty</td>
</tr>
<tr>
<td></td>
<td>Boston Scientific</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medtronic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>St. Jude Medical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Transgenomic (FAMILION)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charles Berul, MD</td>
<td>Johnson &amp; Johnson</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Medtronic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramon Brugada, MD, PhD</td>
<td>Ferrer Incode</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hugh Calkins, MD</td>
<td>Biosense Webster, Inc.</td>
<td>None</td>
<td>Medtronic, Inc.</td>
<td>Medtronic, Inc.</td>
<td>None</td>
<td>iRhythm</td>
</tr>
<tr>
<td></td>
<td>AttriCure, Inc.</td>
<td></td>
<td>Boston Scientific Corp.</td>
<td>St. Jude Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TASER International, Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medtronic Corp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. John Camm, MD</td>
<td>Servier</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>British Heart Foundation—Salary</td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medtronic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xention Discovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston Scientific Corp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingelheim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daichi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Servier</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol Meyers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrick Ellinor, MD, PhD</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Michael Gollob, MD</td>
<td>None</td>
<td>None</td>
<td>Other</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert Hamilton, MD</td>
<td>None</td>
<td>None</td>
<td>Other</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ray Hershberger, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Daniel Judge, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Hervé Le Marec, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>William McKenna, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Silvia Priori, MD, PhD</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Boston Scientific</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PGxHealth (now Transgenomic)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GeneDx</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biotronik</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daiichi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric Schulze-Bahr, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Chris Semsarian, MBBS</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jeffrey Towbin, MD</td>
<td>Transgenomic (FAMILION)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>
## Appendix 2  Continued

<table>
<thead>
<tr>
<th>Authors</th>
<th>Consultant Fees/Honoraria</th>
<th>Speaker's Bureau</th>
<th>Research Grant</th>
<th>Fellowship Support</th>
<th>Board Mbr/Stock Options/Partner</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hugh Watkins, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Harvard Medical School—Royalty</td>
</tr>
<tr>
<td>Arthur Wilde, MD, PhD</td>
<td>PGxHealth (now Transgenomic) Sorin</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stephen Willems, MD, PhD</td>
<td>St. Jude Medical Boston Scientific Corp. Boehringer Ingelheim</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Christian Wolpert, MD</td>
<td>Sorin Boston Scientific St. Jude Medical Medtronic C.R. Bard Biosense Webster</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Douglas Zipes, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

## Appendix 3  Peer Review Disclosures

<table>
<thead>
<tr>
<th>Authors</th>
<th>Consultant Fees/Honoraria</th>
<th>Speaker's Bureau</th>
<th>Research Grant</th>
<th>Fellowship Support</th>
<th>Board Mbr/Stock Options/Partner</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paulus Kirchhof, MD</td>
<td>3M Medica, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Boston Scientific, Omron, MEDA Pharma, Medtronic, Merck, MSD, Otsuka Pharma, Pfizer/BMS, Sanofi-Aventis, Servier, Siemens, Takeda</td>
<td>None</td>
<td>3M Medica/MEDA Pharma, Cardiovascular Therapeutics, Medtronic, Omron, Sanofi-Aventis, St. Jude Medical, German Federal Ministry for Education and Research (BMBF), Fondation LeDucq, German Research Foundation (DFG), European Union</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peter J. Schwartz, MD</td>
<td>BioControl Medical (B.C.M) Ltd., Institut de Recherches Internationales, Servier</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vincent Probst, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Jennifer Cummings, MD</td>
<td>Boston Scientific, Corazon Consulting, Medtronic, Sanofi-Aventis, St. Jude Medical</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steve Ommen, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Steven Markowitz, MD</td>
<td>Boston Scientific, Medtronic, St. Jude Medical</td>
<td>Medtronic, Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Rachel Lampert, MD</td>
<td>Boston Scientific, Medtronic</td>
<td>None</td>
<td>Boston Scientific, Medtronic, St. Jude Medical</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Fred Kusumoto, MD</td>
<td>Medtronic</td>
<td>None</td>
<td>Medtronic</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Mina Chung, MD</td>
<td>American College of Cardiology Foundation, Biotronik, Boston Scientific, Inc., Medtronic, National Institutes of Health Nexcuria, Sanofi-Aventis, St. Jude Medical, University of Texas Health Science, Zoll, Inc.</td>
<td>None</td>
<td>Biotronik, Boston Scientific, Medtronic, National Institutes of Health, St. Jude Medical, Reliant Pharmaceuticals/GlaxoSmithKline</td>
<td>Medtronic, St. Jude Medical</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Raymond Yee, MD</td>
<td>Medtronic</td>
<td>Medtronic</td>
<td>Medtronic</td>
<td>Medtronic</td>
<td>Medtronic</td>
<td>None</td>
</tr>
</tbody>
</table>
References


Acier et al. HRS/EHRA Expert Consensus Statement on Genetic Testing


